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Pulmonary delivery is increasingly seen as an attractive, non-invasive route for the delivery of 
forthcoming protein therapeutics. In this context, here we describe protein complexes with a 
new ‘complexing excipient’ - vitamin B12-targeted poly(ethylene glycol)-block-poly(glutamic 
acid) copolymers. These form complexes in sub-200 nm size with a model protein, suitable 
for cellular targeting and intracellular delivery. Initially we confirmed expression of vitamin 
B12-internalization receptor (CD320) by Calu-3 cells of the in vitro lung epithelial model used, 
and demonstrated enhanced B12 receptor-mediated cellular internalization of B12-targeted 
complexes, relative to non-targeted counterparts or protein alone. To develop an inhalation 
formulation, the protein complexes were spray dried adopting a standard protocol into 
powders with aerodynamic diameter within the suitable range for lower airway deposition. 
The cellular internalization of targeted complexes from dry powders applied directly to Calu-
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3 model was found to be 2-3 fold higher compared to non-targeted complexes. The 
copolymer complexes show no complement activation, and in vivo lung tolerance studies 
demonstrated that repeated administration of formulated dry powders over a 3 week period 
in healthy BALB/c mice induced no significant toxicity or indications of lung inflammation, as 
assessed by cell population count and quantification of IL-1β, IL-6, and TNF-α pro-
inflammatory markers. Importantly, the in vivo data appear to suggest that B12-targeted 
polymer complexes administered as dry powder enhance lung retention of their protein 
payload, relative to protein alone and non-targeted counterparts. Taken together, our data 
illustrate the potential developability of novel B12-targeted poly(ethylene glycol)-
poly(glutamic acid) copolymers as excipients suitable to be formulated into a dry powder 
product for the inhalation delivery of proteins, with no significant lung toxicity, and with 




Pulmonary delivery is increasingly investigated as an alternative route for the delivery of bio-
therapeutics, including proteins [1]. Several proteins and peptides - e.g. cyclosporine A to 
treat asthma, and interleukin-2 to treat pulmonary metastases of renal cell carcinoma [2, 3] -
have been investigated for delivery to the lung. In 2014, an inhaled insulin preparation Afrezza 
was approved by the US Food and Drug Administration [4], and is a currently available option 
in diabetes treatment. However, the lung presents specific barriers for 
macromolecular/protein therapeutics. Susceptibility to enzymatic degradation, poor 
absorption across epithelial barrier, as well as lung induced immunogenicity are significant 
challenges to be addressed if this approach is to be adopted as a viable alternative for protein 
delivery [5, 6]. Covalent attachment of PEG (generally referred to as PEGylation) has evolved 
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as the technique of choice in the bid to increase protein resistance to enzymatic degradation 
and reduced immunogenicity [7, 8]. PEGylation has been shown to enhance protein 
absorption following nasal administration [9, 10], and several studies showed promising 
delivery of PEGylated therapeutics to both the upper and lower respiratory tract for either 
systemic or local therapeutic effects [11, 12].  
To date, chemical conjugation to a therapeutic protein has been used in a vast majority of 
PEGylation studies [13, 14]. However, it does not answer all the challenges of protein delivery, 
with a primary disadvantage being a potential decrease in the protein’s therapeutic effect 
due to irreversible modification/steric shielding of its active site [15, 16]. Non-covalent 
PEGylation, i.e. formation of protein–polymer non-covalent complexes has been explored as 
a potentially suitable alternative.  In a seminal work from Kataoka’s group, stable complexes 
in nanometer size range were assembled from PEG-polyanion or -polycation copolymers and 
charged macromolecules, including proteins [17]. Non-covalent PEGylated complexes were 
also produced from insulin and oligolysine or oligoarginine-type peptide polymers 
functionalized with PEG [18]. An alternative to non-covalent PEGylation based on electrostatic 
interactions between PEG-polyelectrolyte copolymer and selected protein, PEG bearing a 
terminal cholanic moiety (mPEG5kDa-cholane) was utilized to generate polymer conjugates 
through non-covalent hydrophobic interactions with a range of protein and peptides, 
including recombinant human granulocyte colony stimulating factor (rh-G-CSF) [19], 
palmytoilated vasoactive intestinal peptide (VIP) [20], and recombinant human growth 
hormone (rh-GH) [21]. These non-covalent protein-polymer complexes can be assembled by 
simply mixing protein and polymer components under optimized conditions, avoiding the 
often complex conjugation chemistries required for covalent PEGylation. The intrinsically 
reversible nature of these interactions potentially allow complex disassembly under specific 
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conditions - e.g. those found in the proximity of the intended biological target - which 
addresses the potential disadvantages covalent conjugation discussed above.  
In this work, we present a further development in the non-covalent PEGylation approach, by 
engineering ligand-targeted non-covalent complexes which exploit cell-specific transport 
pathways for the intracellular delivery of therapeutic protein. To the best of our knowledge, 
this is the first example of ligand-targeted polymer-protein ionic complexes used for 
intracellular delivery of complexed protein.  
Accordingly, here we engineered cyanocobalamin (vitamin B12) ligand-targeted complexes 
based on B12-PEG-poly(glutamic acid), using lysozyme as a model protein cargo. A family of 
B12-PEG-poly(glutamic acid) copolymers with linear and miktoarm polymer topology was 
synthesized. These are used as a new ‘complexing excipient’ to assemble nano-sized 
complexes with the model protein, which can then be spray-dried into inhalable dry powders 
for inhalation delivery to the lung epithelium. In in vitro studies, Calu-3 cells were chosen as 
lung epithelial model and were grown as polarized layers in air-liquid interface culture (AIC) 
conditions to promote mucus secretion, normally considered to mimic lung physiological 
conditions [22]. Data show enhanced cellular internalization of targeted complexes, relative 
to non-targeted counterparts or ‘free’ protein. Toxicity studies demonstrated no complement 
activation, and in vivo lung tolerability assessment shows no significant signs of lung 
inflammation on repeated administration of formulated dry powders to healthy mice. In vivo 
lung deposition data illustrate ability of the complexes formulated as dry powders to deposit 





α-dibenzocyclooctyne-vitamin B12 (DBCO-B12). Cyanocobalamin (vitamin B12, 50 mg, 0.037 
mmol, 1 eq.) was dissolved in anhydrous DMSO (5 mL) under inert atmosphere. 1,1’-
carbonyldiimidazole (CDI) (9.7 mg, 0.060 mmol, 1.6 eq.) was then added, and the reaction 
was stirred at 30°C for 1.5 h followed by addition of a solution of dibenzocyclooctyne-amine 
(30 mg, 0.11 mmol, 3 eq.) in DMSO (5 mL). The resulting solution was stirred at room 
temperature protected from light for 24 h. The mixture was then precipitated in diethyl ether, 
centrifuged, and the solid residue was dissolved in methanol and purified by preparative-TLC 
(iPrOH : n-BuOH : H2O : NH4OH 30:45:21:4). The product was extracted from the relevant TLC 
band using methanol, then the resulting suspension was filtered, and after solvent removal 
under reduced pressure DBCO-B12 was isolated as a pink-red solid. Yield: 11 mg, 22 %. Mass 
spectrometry and RP HPLC (Supporting Information, Figure S1) confirmed the purity of the 
isolated DBCO-B12: expected m/z [M-Na++] theor. 851.85, found 851.33. 
B12-PEG3k-mik-(GA17)3 and B12-PEG3k-lin-(GA24). Azide-PEG3k-mik-(GA17)3 (40 mg, 0.0022 
mmol, 1 eq.) or azide-PEG3k-lin-(GA24) (100 mg, 0.013 mmol, 1 eq.) (Supporting Information, 
Figure S1 and S2) were dissolved in deionized water (3 mL). DBCO-B12 (7 mg, 0.004 mmol, 2 
eq., or 44 mg, 0.026 mmol, 2 eq.) to form B12-PEG3k-mik-poly(GA17)3 and B12-PEG3k-lin-(GA24) 
copolymers, respectively was dissolved in DMSO (3 mL) and then added to the round bottom 
flask containing the relevant copolymer. The mixture was stirred at room temperature 
protected from the light overnight. The solution was then dialyzed (MWCO 3.5 kDa) against 
deionized water, and after freeze-drying B12-PEG3k-mik-(GA17)3 and B12-PEG3k-lin-(GA24) were 
isolated as pink solids.  
B12-PEG3k-mik-(GA17)3 yield: 39 mg, 91 %. 1H NMR (400 MHz, D2O, δ, ppm): 4.44-4.28 (bs, 
HNCHCO), 3.75-3.60 (s, OCH2 of PEG), 2.52-1.90 (m, CH2CH2COOH). Mn,NMR = 21.0 kDa, Mn,SEC 
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= 4.8 kDa, ĐSEC = 1.59. B12-PEG3k-lin-(GA24) yield: 121 mg, 96 %. 1H NMR (400 MHz, D2O, δ, 
ppm): 7.83-7.66 (s, CHaromatic), 7.50-7.33 (s, CHaromatic), 4.47-4.05 (bs, HNCHCO), 3.76-3.58 (s, 
OCH2 of PEG), 2.50-1.86 (m, CH2CH2COOH). Mn,NMR = 9.8 kDa, Mn,SEC = 4.4 kDa, Đ = 1.23.  
Untargeted mPEG2k-polyGA copolymers. Linear mPEG2k-lin-GA30 and miktoarm mPEG2k-mik-
(GA10)3 copolymers were synthesized in our previous work.[23] 
Preparation of polymer-protein complexes. (mPEG2k-lin-GA30)-lysozyme complexes were 
prepared at relative molar charge ratios r = 2.5 where r is the charge ratio between the 
number of glutamic acid residues in the copolymer (negatively charged at physiological pH), 
and the 17 lysine and arginine residues (positively charged at physiological pH) of lysozyme. 
Polymers and protein were separately dissolved in phosphate buffer (PB, 10 mM, pH 7.4) and 
appropriate aliquots were mixed to achieve r = 2.5. For example, to make 1 mL of complexes 
at 70 µg mL-1 protein concentration for nanoparticle tracking analysis, 21 µg of mPEG2k-lin-
GA30 and 70 µg of lysozyme were mixed in 1 mL of 10 mM PB. Specific protein and polymer 
concentrations are reported in the description of individual experiments below. 
To prepare targeted polymer-protein complexes, mPEG2k-lin-GA30 and B12-PEG-polyGA 
copolymers were mixed at relative molar ratios of 85:15 (mol:mol), respectively. Polymers 
mixture and lysozyme were then mixed at relative molar charge ratio of 2.5.  
To monitor protein cellular uptake, lysozyme used in all subsequent studies was fluorescently 
labelled using sulfo-Cyanine 5 (Cy5) succinimidyl (NHS) ester (Lumiprobe), according to 
manufacturer protocol. After dialysis, protein concentration and degree of labelling were 




Nanoparticle Tracking Analysis (NTA). The hydrodynamic diameter of B12-targeted and non-
targeted polymer-protein complexes was measured by NTA (Nanosight LM14). All 
measurements were performed at 25°C. NTA 2.0 Build 127 software was used for data 
acquisition and analysis. The samples were measured for 80 s. Mean size ±SD values 
correspond to the arithmetic values calculated for all the particles analyzed by the software. 
Polymer-protein complexes were prepared at charge ratios of 2.5 in 10 mM phosphate buffer, 
pH 7.4. Protein concentration was kept constant (70 µg mL-1) for all measurements. Free 
protein and polymers were used as controls. 
Formulation of complexes as dry powders by spray-drying. The complexes were formulated 
into dry powders following procedure optimized previously [24]. The composition of dry 
powders was: 0-10 % (w/w) protein-polymer complexes, 10 % (w/w) leucine, 6.6 % (w/w) 
phosphate buffer salts, and trehalose as bulking agent (up to 100 % (w/w)).  
Cell culture. Human airway epithelial cells (Calu-3) were routinely cultured in DMEM/F-12 
medium. Medium was supplemented with Foetal Bovine Serum (FBS, 10 % v/v), non-essential 
aminoacids (1 % v/v), L-glutamine (1 % v/v), penicillin (100 units mL-1) and streptomycin (0.1 
mg mL-1). DPBS and trypsin/EDTA were used to wash and detach adherent cells in the process 
of cell splitting. Cells were always incubated at 37°C and 5 % CO2. 
Culture of cells on Transwell® inserts. Calu-3 cells were seeded at 1x106 cells cm-2 on 
Transwell® inserts (12 mm diameter, 0.4 µm pore size; Corning Life Sciences, USA) and 
cultured for 14 days, with medium replacement every two days. Cells were cultured using air-
interface culture (AIC) conditions [22] known to promote mucus secretion, starting from day 
2 post-seeding on Transwell® inserts. Cell confluence and cell layer integrity before 
treatments with test samples was confirmed by transepithelial electrical resistance (TEER) 
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measurements (EVOM voltohmmeter, World Precision Elements, USA). Cells included in the 
experiments always had values higher than 550 Ω cm-2.  
cDNA synthesis and quantitative PCR analysis. Total RNA was extracted using RNeasy Mini 
Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. RNA concentration 
and purity were assessed using NanoDrop spectrophotometer (Thermo Scientific, 
Wilmington, DE). Five-hundred nanograms of total RNA were reverse transcribed to 
complementary DNA (cDNA) by QuantiTect Reverse Transcription Kit (Qiagen). Genomic DNA 
elimination was carried out twice, during RNA extraction and before the cDNA synthesis. qPCR 
reactions were performed in 96-well white-walled plates using 2x Brilliant II SYBR® Green 
QPCR Master Mix (Agilent) with the following primer sets: cubilin forward primer: 5′-
CGTGGAACACACAAACTTTAGG-3′ and reverse primer: 5′-CCAGTGAGGGGATCTGATTG-3′; 
TCN2 receptor (CD320) forward primer: 5′-CACCCACCAAGTTCCAGTGCCG-3′ and reverse 
primer: 5′-GTTCCACAGCCGAGCTCGTCG-3′; TCN2 forward primer: 5′-
GCTGGTTGTGGCACAGTA-3′ and reverse primer: 5′-AGGTCCACAGGCCATCAAT-3′. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a standardization control 
(forward primer: 5’-AGGTGAAGGTCGGAGTCAAC-3’ and reverse primer: 5’-
GATGACAAGCTTCCCGTTCT-3’).  ∆∆Cq method was used to calculate relative gene expression. 
Cellular uptake of pyr-B12 fluorescent probe.  Calu-3 and Caco-2 cells were cultured on 
Transwell® inserts over 14 and 21 days, under air-liquid or liquid-liquid interface respectively. 
Culture medium was removed from filter-cultured cells and replaced with Hank’s Balanced 
Salt Solution (HBSS) in both Transwell® compartments for TEER measurements. Following the 
measurement of TEER, pyr-B12 probe (synthesized as described in the Supporting Information) 
was dissolved in DMEM medium without phenol red at concentration of 200 µg mL-1, and 500 
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µL of this solution was added to the apical chamber of the Transwell® insert. Cells were then 
incubated at 37°C for 3 hours and analyzed by flow cytometry (Beckman Coulter Astrios EQ) 
in at least triplicate experiments, with more than 10,000 cells measured in each sample. 
The effect of a competitive ligand on receptor-mediated cellular internalization of fluorescent 
pyr-B12 probe was studied in the presence of an excess of free vitamin B12; 500 µL of a 1.0 mg 
mL-1 solution of cyanocobalamin (B12) in DMEM medium was added to the apical chamber of 
Transwell® inserts. Cells were subsequently incubated at 37°C for 30 min, then the medium 
was replaced with a stock solution of fluorescent pyr-B12 probe (500 µL, final probe 
concentration 200 µg mL-1) plus free vitamin B12 at the same concentration as the pre-
incubation solution. Cells were incubated at 37°C for 3 hours, fixed with formaldehyde and 
analyzed by flow cytometry (Beckman Coulter Astrios EQ). Experiments were made in at least 
triplicates, with more than 10,000 cells measured in each sample.  
Cellular internalization of polymer-protein complexes applied as suspension. Calu-3 cells 
were cultured on Transwell® inserts over 14 days as described above. Culture medium was 
removed and replaced with Hank’s Balanced Salt Solution (HBSS) prior to the experiment.  
Polymer-protein complexes were applied as a suspension in HBSS at concentration of 3 µg 
mL-1 protein. Following TEER measurement (to assess cell layer integrity), the complexes 
suspension (0.5 mL) was added to the apical chamber of the Transwell® insert. Cells were then 
incubated at 37°C for 3 h and fixed with 2% formaldehyde followed by analysis by flow 
cytometry in at least quadruplicate experiments, with more than 10,000 cells measured in 
each sample. 
The effect of a competitive ligand on receptor-mediated uptake of B12 targeted complexes 
was studied in the presence of an excess of free cyanocobalamin (vitamin B12). Firstly, 500 µL 
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of a 1.0 mg mL-1 solution of cyanocobalamin (B12) in HBSS was added to the apical chamber 
of quadruplicate Transwell® inserts. Cells were then incubated at 37°C for 30 min following 
addition of targeted polymer-protein nanocomplex suspension (500 µL, final protein 
concentration 3 µg mL-1). Cells were incubated again at 37°C for 3 h, washed and fixed before 
analyzed by flow cytometry. Experiments were made in at least quadruplicate, with more 
than 10,000 cells measured in each sample.  
Cellular internalization of protein-polymer complexes applied as dry powder formulations. 
Calu-3 cells were cultured on Transwell® inserts as previously described. Dry powders were 
sprayed twice (2 mg per dose) using a Dry Powder InsufflatorTM model DP4-M® (Penn-
Century®) into the Transwell® inserts as follows. Four Transwell® inserts were placed into a 
desiccator at equal distance from the center [25] (also illustrated in Supporting information, 
Figure S13). 2 mg of dry powder formulations were then sprayed twice from a Penn-Century® 
device. Next, 500 µL of Hank’s Balanced Salts Solution (HBSS) were added to the basolateral 
chamber of the Transwell® inserts and cells were incubated at 37°C and 5% CO2 for 3 h. Cells 
were then detached with trypsin/EDTA, washed twice with DPBS, fixed with 2% formaldehyde 
and lysozyme uptake was analyzed by flow cytometry in quadruplicate experiments, with 
more than 10,000 cells measured in each sample. 
 
In vitro assessment of complement activation. [B12-PEG-lin-(GA30)]-lysozyme complexes or 
free lysozyme were incubated with normal human serum (NHS) and the residual hemolytic 
capacity was measured to study the complement activation. NHS was received from healthy 
volunteers (Phlebotomy Department, Nottingham University Hospitals, NHS Trust) and, once 
sensitized, suspended at a final concentration of 1x108 cells mL-1 in veronal-buffer saline 
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(VBS2+, containing 0.5 mM Mg2+ and 0.15 mM Ca2+). VBS2+ and NHS were mixed with 
lysozyme-polymer complexes or free lysozyme at a final protein concentration of 1.12 mg mL-
1 so that the final dilution of NHS in the reaction mixture was 1/4 (v/v) in a final volume of 400 
µL. The suspension was incubated at 37°C for 60 min under gentle stirring. The mixture was 
then diluted 1/25 (v/v) in VBS2+ and aliquots at different dilutions were added to a specific 
volume of sensitized sheep erythrocytes. The suspensions were incubated for 45 min at 37°C 
under gentle stirring and the reaction was then stopped by adding ice-cold NaCl (0.15 M). The 
mixture was centrifuged at 2,000 rpm for 5 minutes to precipitate un-lysed erythrocytes. The 
supernatant was collected and the optical density was measured at λ = 415 nm (Cary Eclipse 
Spectrophotometer).  
Mixture of sensitized sheep erythrocytes in VBS2+ without NHS was used here as positive 
control and employed to correct the baseline absorbance values. Mixture of sensitized sheep 
erythrocytes with addition of distilled water which would result in total hemolysis was utilized 
as negative control. In this study, the data were expressed as the percentage of complement 
activation relative to 100 % complement activation observed with the positive control 
samples. 
In vivo evaluation of the complexes formulated as dry powders 
Animals and husbandry conditions. Female BALB/c mice (Charles River, Arbresle, France) 
were kept under conventional housing conditions (22 ± 2°C, 55 ± 10 % humidity, and 12-hour 
day/night cycle). All studies and manipulations were approved by the CEBEA ethical 
committee of the Faculty of Medicine, ULB (Commission d’Ethique du Bien-Etre Animal, 
Université libre de Bruxelles, Belgium) (Ethical protocol N°585N). The laboratory federal 
agreement number is LA 1230568. 
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Characterisation of dry powder formulations emitted by the dry powder insufflator. Aerosol 
particles generated from Dry Powder InsufflatorTM model DP4-M® (Penn-Century®, 
Philadelphia, USA) were confirmed to be suitable for endotracheal administration into the 
mice by using a Spraytec® laser diffractometer. The emitted aerosol, created using Dry 
Powder InsufflatorTM model DP4-M®, was presented dispersed in air directly and 
perpendicular to the laser beam for size measurement. For all formulations tested (Table 1) a 
loading powder mass of 2 mg was evaluated (n=10). High emitted mass values (> 80%), 
particle size D50 ≤ 5 µm and RSD values ≤ 25% for emitted masses were considered suitable 
for the administration of dry powder formulations to the mice (Supporting information, 
Table S1). 
Local pulmonary tolerance of the complexes. Solution of LPS and dry powder formulations 
were administered by the non-invasive endotracheal route using an aerosolizing system 
(MicrosprayerTM model IA-1C®) or a dry powder insufflator designed for mice (Dry Powder 
InsufflatorTM model DP4-M®, Penn-Century), respectively, as described elsewhere [26, 27].  
Composition of formulations tested is shown in Table 1. Five groups were compared: (i) non-
treated mice negative control (i.e. group baseline, n=6), (ii) mice treated with unlabeled dry 
powder (denoted as UDP)  (control dry powders, with no protein nor copolymers, excipients 
only) (n=5), (iii) mice treated with unlabeled dry powder-protein (UDP-P) (dry powders 
containing lysozyme, but not polymers ) (n=5), (iv) mice treated with unlabeled dry powder 
containing protein-targeted complexes (UDP-TC) (dry powders containing 85:15 [mPEG2k-lin-
GA30/B12-PEG3k-lin-(GA24)]-lysozyme complexes) (n=5), and (v) mice treated with a 
lipopolysaccharide (LPS) solution (single administration of 1 µg dose) as positive control (n=6). 




Bronchoalveolar lavage fluids (BALFs) were analyzed in terms of cell composition (total and 
differential cell count) and pro-inflammatory markers concentration (cytokines IL-1β, IL-6, 
and TNF-α), as previously described [27]. Mice were euthanized by a lethal intraperitoneal 
injection of 12 mg sodium phenobarbital (Nembutal®, Ceva Santé Animale, Brussels, Belgium) 
8 h (for the LPS group) or 24 h (for the dry powder inhaler groups) after the last inhaled 
administration. BALFs were collected using a 20-gauge cannula (Surflo® catheter, Terumo, 
Leuven, Belgium) with 3 flushes of 0.7 mL cold PBS and conserved on ice until total cell count 
analysis (Z2TM Coulter Counter®, Beckman Coulter, Suarlée, Belgium). BALF were centrifuged 
at 160 x g at 4°C, supernatants were collected and conserved at -80°C for cytokine 
quantification. Differential cell counts were performed on cytospin preparations after staining 
with May Grünwald and Giemsa (Sigma-Aldrich). A total of 200 cells were counted per slide 
and were referred to as alveolar macrophages, lymphocytes or polymorphonuclear 
neutrophils according to their morphology. Cytokine concentrations were determined by 
ELISA for mouse IL-1 β, IL-6, and TNF-α (DuoSet® ELISA, RnD Systems) according to the 
manufacturer’s protocols. The limits of quantification for the techniques used were 15.6 pg 
mL-1 for IL-1β and IL-6, and 31.3 pg mL-1 for TNF-α. 
In vivo pulmonary deposition and retention. The deposition of the dry powder formulations 
was evaluated after pulmonary delivery. Lysozyme-Cy5-containing DPI formulations (LDP-P, 
LDP-TC and LDP-NT, composition in Table 1) were administered to mice (2 mice per group) by 
the endotracheal route, as described above. After 0, 3 and 14 hours, mice were sacrificed 
using sodium pentobarbital, the lungs were collected and blocked using Optimum Cutting 
Temperature (OCT) solution (Tissue-Tek® OCT compound, Sakura). Five non-serial cryo-
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sections of 7 µm per lung were prepared and mounted on SuperFrostTM slides (Thermo Fischer 
Scientific) using a DAPI solution (DAPI Counterstain, Abott Laboratories, Des Plaines, IL, USA) 
and finally covered with a coverslip. The slides were observed under a Leica SP8 confocal 
microscope (Leica Microsystems, Diegem, Belgium) with filters (Zeiss, Germany) at 546 nm 
(bandwidth 12 nm) and 610 nm (bandwidth 65 nm) used for excitation and emission, 
respectively, for Cy5 labelled protein. Due to sub-optimal spectral overlap, prolonged 
exposure (1000 ms) was needed to acquire images. A DAPI filter (Zeiss) was used for DAPI. 
The images were processed (i.e. fluorescence intensity, mean grey values) using ImageJ 
Software (National Institutes of Health, USA). Quantitative data are presented as the ratio of 
average of the grey mean values of Cy5 to DAPI areas (n=5 tissue slices), as described in 
Dawson et al [28]. 
 
Table 1. Composition of dry powder formulations used in the in vivo studies.  
a corresponding to ~ 5 % w/w of lysozyme. 
UDP-P denotes dry power containing unlabeled protein, UDP-TC denotes dry power containing unlabeled 
protein complexes with B12-targeted polymer, LDP-TC denotes dry powder containing labelled protein 
complexes with B12-targeted polymers, LDP-NT denotes dry powder containing labelled protein with non-
targeted polymer.  
Unlabeled dry powder formulations were used for local pulmonary tolerance studies, and Cy5-labelled protein 

















Trehalose   
(% w/w) 
 UDP 0 % complexes 10 6 Up to 100 
unlabeled dry 
powder (UDP) 
UDP-P 5 % lysozyme 10 6 Up to 100 
 
UDP-TC 
10  % targeted 
complexesa 10 6 Up to 100 
 LDP-P 5 % lysozyme 10 6 Up to 100 
Cy5 labelled dry 
powder (LDP) LDP-TC 
10 % targeted 
complexesa 10 6 Up to 100 
 
LDP-NT 
10 % non-targeted 




Results and Discussion 
Delivery of therapeutic macromolecules into, or across cells forming epithelial barrier is a 
recognized therapeutic challenge. Potential solutions include approaches that exploit normal 
biological pathways of cellular internalization and transcytosis of nutrients, vitamins, as well 
as macromolecules [29, 30]. In our previous study, we demonstrated that vitamin B12 can i) 
be used as a ligand to enhance internalization of model sub-200 nm polystyrene particles by 
epithelial cells, ii) influence their intracellular trafficking pathways, and iii) enhance transport 
of decorated nanoparticles across Calu-3 cell layer [31, 32]. Here, we apply the B12 directed 
cellular internalization and transport to achieve targeted delivery of polymer-protein 
complexes in vitro and in vivo. Accordingly, we synthesized a family of targeted B12-PEG3k-
polyGA copolymers and utilized these to generate polymer-protein complexes via ionic, non-
covalent interactions between polymer and model protein charged functionalities. 
 
Synthesis of targeted B12-PEG-polyGA copolymers. The B12-targeted copolymers, B12-PEG-
polyGA (Figure 1), were produced through a modification of an approach we developed 
previously for synthesis of analogous non-targeted counterparts (Supporting information, 
Figures S2 and S3) [23]. The synthesis of both linear and miktoarm B12-targeted polymers 
started from O-(2-aminoethyl)polyethylene glycol (3.0 kDa), and involved N-
carboxyanhydride (NCA) polymerization of γ-benzyl-L-glutamate N-carboxyanhydride (NCA) 
to generate, after hydrolysis of the benzyl ester protecting groups, a poly(glutamic acid) 
polyanion block. B12-targeted copolymers were prepared from a 3kDa PEG block, which is 
longer than the 2 kDa PEG used for the non-targeted analogues, to potentially increase the 
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exposure of B12 ligands at the surface of the corresponding protein-polymer complexes.  
 
Figure 1. Chemical structure of non-targeted (top), and B12-targeted (bottom) PEG-poly(glutamic acid) 
copolymers with linear and miktoarm topology.  
 
In the final step, the required B12 ligand was introduced in linear azide-PEG3k-lin-(GA24) (1) and 
miktoarm azide-PEG3k-mik-(GA17)3 (2) intermediates by copper-free strain-promoted Huisgen 
1,3-dipolar cycloaddition (Supporting information, Figures S2 and S3) [33, 34]. To this aim, 
α-dibenzocyclooctyne-vitamin B12 (DBCO-B12) was synthesized by activating the CH2OH group 
at C5 of cyanocobalamin pentose moiety with carbonyldiimidazole(CDI) for 30 min in DMSO, 
followed by the addition of commercially available α-dibenzocyclooctyne-amine, to form a 
stable carbamate linker. Reaction with the azide-containing intermediates (1) and (2) in 
water-DMSO followed by dialysis afforded the final linear B12-PEG3k-lin-(GA24) and miktoarm 
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B12-PEG3k-mik-(GA17)3 protein-complexing copolymers (Figure 2).  
 
 
Figure 2. Synthesis of vitamin B12-targeted B12-PEG3k-lin-(GA24) copolymers. Reactions and conditions:  a) i. 1,1′-
carbonyldiimidazole, ii. dibenzocyclooctyne-amine (DBCO-amine) b) DBCO-B12, DMSO/H2O, overnight.  B12-
PEG3k-mik-(GA17)3 was prepared in an analogous manner, from miktoarm azide-PEG3k-mik-(GA17)3 intermediate 
(2) (Supporting information, Figure S2). 
 
The successful click conjugation of DBCO-B12 to azide-PEG3k-b-polyGA was confirmed by 2D 
Heteronuclear Single-Quantum Correlation (HSQC) and 1D 1H NMR (Figure 3). Due to the 
complexity of the NMR spectra of B12-PEG3k-lin-(GA24) and B12-PEG3k-mik-poly(GA17)3 
copolymers, model low molecular weight azides and cyclooctynes were synthesized and 
analyzed to identify diagnostic peaks which would allow us to monitor this reaction 
(Supporting information, Figure S6). The α-CH2 protons of the cyclooctyne ring were found 
to be particularly suitable for this, due to their relatively large 1H NMR downfield shift (~ 0.7-




Figure 3. 1H NMR and HSQC spectra of the α-CH2 proton signal of the α-dibenzocyclooctyne-amine before (a1, 
a2) and after (b1, b2) the copper-free click conjugation of DBCO-B12 to azide-PEG3k-lin-(GA24) (1) (left) and 
azide-PEG3k-mik-(GA17)3 (2) (right).  
 
More specifically, one of the two α-CH2 protons of α-dibenzocyclooctyne-B12 (DBCO-B12) at 
5.0 and 56 ppm, for 1H and 13C, respectively, was found to shift to 5.9 and 52 ppm, following 
click cycloaddition with linear N3-PEG3k-lin-(GA24) azide precursor (1), which confirmed 
successful conjugation. For the miktoarm B12-PEG3k-mik-poly(OBn-GA17)3 copolymer, 
although the quality of the HSQC NMR data was not suitable for confirming the presence of 
the desired product due to a poor signal intensity, 1D 1H NMR indicate the appearance of the 
diagnostic signal at 5.9 pm for the clicked B12 adduct, thus confirming the success of the click 
reaction. Size exclusion chromatography of the purified final polymers confirmed complete 
removal of the excess of unreacted α-dibenzocyclooctyne-B12 (Supporting information, 
Figure S4), whilst efficiency of functionalization was estimated by UV-vis spectrometry (λ = 







Targeted PEG-poly(GA)-lysozyme complexes. PEG-poly(GA) copolymer-protein complexes 
with lysozyme as a model protein cargo were assembled using a mixture of B12-targeted and 
non-targeted PEG-poly(GA) copolymers. In this study a 15:85 molar ratio, respectively was 
selected. We appreciate that the density of surface exposed targeting ligand, and indeed its 
clustering, has a profound effect on nanoparticles internalization, as illustrated in previous 
research from our and other groups. Using another nano-sized targeted system with folate 
ligand we previously achieved a reasonable level of cellular internalization for a range of 
ligand ‘surface functionalization’ [33], and based on that a 15:85 ratio was considered as a 
good starting point. A polymer-protein relative molar charge ratio of 2.5 - defined as the molar 
ratio between glutamic acid polymer repeating units, assumed to be all negatively charged at 
pH 7.4, and cationic amino acids of lysozyme – was used, as we have previously shown 
efficient complexation of PEG-poly(GA) copolymers to lysozyme under these conditions [23]. 
The data (Supporting information, Figures S10 and S11) indicate a formation of polymer-
protein complexes in the 120-180 nm size range - suitable size for endocytosis - for targeted 
and non-targeted systems, as assessed by nanoparticle tracking analysis (NTA). Gel 
electrophoresis analysis of complexes suspended in cell culture medium shows that majority 
of lysozyme remains complexed during 3 hours of cellular internalization study, when 
suspended in cell growth medium, and is released on change in pH to 4.5 in simulated 
lysosomal environment (Supporting information, Figure S12). 
Expression of mRNA and function of B12 receptors. The presence of components involved in 
vitamin B12-specific transport pathways has been widely confirmed in intestinal epithelium 
models, such as in vitro cultures of Caco-2 cells [34, 35], and B12 receptors have been 
successfully targeted for intestinal delivery of proteins [36, 37], and in vitro transport of 
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nanoparticles across intestinal epithelium. In the latter, B12 transport can occur through two 
different receptors: cubilin and transcobalamin receptor (CD320, or TCN2R) [38]. Evidence of 
vitamin B12 transport mechanisms in the lung epithelium, and its in vitro cell models, is scarce. 
We have previously demonstrated, using a combination of molecular biology and 
immunostaining techniques, that Calu-3 bronchial cell line expresses the B12-IF receptor 
(cubilin), the transcobalamin receptor (‘TCN2 receptor’, CD320), and the transcobalamin II 
protein (‘TCN2’) [31].  The present work confirms (Figure 4a) at mRNA level, expression of 
cubilin (human CUBN gene), transcobalamin receptor (CD320 gene) and transcobalamin II 
protein (human TCN2 gene).  mRNA expression of the cubilin receptor was found to be very 
low, relative to control gene expression. It should be noted that the mechanism of vitamin 
B12 uptake via cubilin receptor requires the initial complexation of B12 with Intrinsic Factor (IF, 
or Gastric Intrinsic factor, GIF), a glycoprotein that is produced by parietal cells in the stomach 
[39]. Thus it may not be surprising that cubilin-dependent transport pathway would be 
downregulated in Calu-3 cells, which originate from the lung tissue. Conversely, 
transcobalamin receptor (CD320)-mediated transport requires initial binding of vitamin B12 to 
TCN2 carrier protein, followed by uptake of the resulting complex by CD320 (transcobalamin) 
receptor-mediated endocytosis [40, 41]. The TCN2 protein in this complex is eventually 
degraded in the lysosomes, releasing cobalamin (vitamin B12) which is further processed 
intracellularly [40]. In this work, expression of mRNA for transcobalamin II protein in Calu-3 
cell culture was confirmed by qPCR (Figure 4a) while in a previous study we have shown TCN2 
protein expression in Calu-3 cells in a qualitative manner, by immunostaining [31]. Taken 
together, our results indicate that Calu-3 cell model used in this study possess all the 
functional components required for cellular internalization of cobalamin (vitamin B12) 
molecules via transcobalamin (CD320) receptor-mediated transport. 
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Figure 4.  a) mRNA expression of cubilin, CD320 and TCN2 relative to GAPDH (as housekeeping gene) by Calu-3 
cells. b) Cellular internalization of pyr-B12 fluorescent probe by Calu-3 cells in the presence or absence of free 
vitamin B12 competitive ligand. Control: untreated cells. One-way ANOVA was used for statistical analysis. *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. Flow cytometry conducted at λex 401 nm and λem 421 nm.  
 
To confirm functional, endocytic activity of vitamin B12 receptors in Calu-3 epithelial model 
employed in this study, we designed a low molecular weight B12-fluorescent probe, pyr-B12. 
This O-alkyl pyranine-based fluorescent compound was selected due to its structural 
similarity to Lucifer Yellow, which is known to have low cell membrane permeability, while 
possessing functionalities appropriate for conjugating to vitamin B12. Accordingly, O-alkyl 
pyranine blue-fluorescent dye with narrow Stokes shift (λex = 401 nm, λem = 421 nm), was 
linked to the 5’ hydroxyl group of the ribose ring of cyanocobalamin, in a similar way to the 
approach followed for the synthesis of DBCO-B12, in four steps, starting from 8-
hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine), and cyanocobalamin (B12) 
(Supporting Information, Figure S8). For comparative purposes, in another experiment 
cellular internalization of pyr-B12 by the established cell model expressing both cubilin and 
TCN2 B12 receptors, intestinal Caco-2 cell line [42, 43], was also assessed (Supporting 
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Information, Figure S9). Data in Figure 4b show a significant reduction of pyr-B12 cellular 
internalization in the presence of an excess of ‘free’ vitamin B12 competitive ligand. This 
indicates a prominent, but not exclusive, role of B12-specific transport in the cellular 
internalization of pyr-B12 probe, likely occurring through TCN2 receptor mediated transport.  
Complement activation. An undesired effect associated with pulmonary delivery is the 
immunogenicity of drug delivery systems, protein cargoes, or both. Accordingly, 
immunogenic formulations/proteins can lead to reduced efficacy, inflammation, anaphylaxis 
and autoimmunity. These side-effects can result from a range of factors, including the intrinsic 
nature of specific protein therapeutics, and their tendency to aggregate, either during storage 
or in vivo, which leads to their increased immunogenicity [44-46]. The complement system 
has key roles in innate and adaptive immune responses. Although most complement proteins 
are generated in the liver as inactive precursor enzymes, the lung may also act as a local 
source of complement proteins [47]. In this study normal human serum was selected as a 
source of complement proteins, due to the ease of serum availability compared to the 
extraction of complement proteins present in the lungs. The ability of free lysozyme and B12-
targeted lysozyme complexes to activate the complement system was evaluated (Figure 5). 
At the concentration investigated (1.12 mg mL-1), ‘free’ lysozyme was found to activate the 
complement system to around 50% level, whilst for lysozyme complexes with targeted B12-
PEG3k-poly(GA) polymers, these values decreased to 16 and 25% when linear or miktoarm 
copolymers were used, respectively (Figure 5).  
PEG is known to decrease protein immunogenicity, following covalent PEG-protein 
conjugation [48]. Therefore, the reduction in immunogenic response observed for the PEG-
poly(GA)-lysozyme complexes could be ascribed to the similar effect of steric stabilization 
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provided by PEG chains on the complexed lysozyme. Interestingly, linear polymer showed 
somewhat higher protection than miktoarm copolymers, potentially indicating some 
differences in their complexation with the protein.  Taken together, these results suggest that 
protein complexation with PEG-poly(GA) copolymers can reduce the complement activation 
triggered by model protein, lysozyme, and that, within specific contexts, this approach could 
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Figure 5.  Complement activation by free lysozyme, linear [85:15 mPEG2k-lin-GA30/B12-PEG3k-lin-(GA24)]-lysozyme 
and miktoarm [85:15 mPEG2k-mik-(GA10)3/B12-PEG3k-mik-(GA17)3]-lysozyme complexes. The data expressed as 
the percentage of complement activation relative to 100 % complement activation observed with the positive 
control samples (where no haemolysis have occurred). Lysozyme concentration was kept constant to 1.12 mg 
mL-1 for all samples. One-way ANOVA was used for statistical analysis. *** p < 0.001, **** p < 0.0001. 
 
Cellular internalization of B12-targeted protein-polymer complexes in vitro.  Data in Figure 6 
demonstrate significantly increased cellular internalization of targeted B12-PEG3k-poly(GA)-
protein complexes, compared to ‘free’ Cy5-lysozyme or non-targeted mPEG2k-poly(GA)-
lysozyme complexes. Interestingly, this effect was independent on the topology of the 
complexing polymers - linear B12-PEG3k-lin-(GA24), vs. miktoarm B12-PEG3k-mik-(GA17)3.  
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Importantly, cellular internalization of targeted complexes decreased significantly in the 
presence of an excess of ‘free’ vitamin B12 competitive ligand, confirming a prominent, but 
not exclusive, role of a vitamin B12-specific transport mechanism in the complexes trafficking 
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Figure 6. Cellular internalization of B12-targeted and non-targeted PEG-poly(GA)-Cy5-lysozyme complexes by 
Calu-3 cells grown as polarized epithelial cell layers. Suspensions of complexes were applied at protein 
concentration of 3 µg mL-1 and incubated with cells for 3 h prior to flow cytometry analysis. Cells were grown as 
polarized layers on Transwell supports under air-liquid interface conditions. ‘+ free B12’ denotes presence of 
excess of soluble B12 competitive ligand in the medium, ‘free lysozyme’ indicates that cells were treated with a 
solution of Cy5-lysozyme in the absence of PEG-poly(GA) complexing copolymers. One-way ANOVA was used for 
statistical analysis. ** p < 0.01, *** p < 0.001.  
 
The observed level of cellular internalization of ’free’ cy5-lysozyme (Figure 6) was somewhat 
unexpected.  Data on similar experiments on cellular uptake of lysozyme are scarce, but 
recent in vivo studies reported on absorption of lysozyme in the intestinal tract [49], which 
appears to be occurring by non-saturable and saturable processes, the latter pointing to an 
involvement of endocytic pathway(s). Furthermore, it has recently been suggested that 
receptor-mediated endocytosis of lysozyme in renal proximal tubules may be mediated by 
megalin and cubilin [50]; the mRNA expression, although at a very low level, of the latter 
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receptor was confirmed in the cell model used in this study. Furthermore it should be noted 
that complexation of lysozyme with non-targeted copolymers resulted in similar level of 
internalization as for ‘free’ lysozyme (Figure 6), a result that would be unexpected if one 
considers that PEGylation is generally recognized to reduce cellular uptake of colloidal size 
particulates [51].  As noticed above, the B12-mediated pathway does not appear to be an 
exclusive transport mechanism for tested systems in the cellular model used, and hence 
further studies to decipher internalization pathways would be needed, e.g. [52]. These are 
however beyond the scope of the current work that aims to design targeted excipients for 
inhalable dry powder formulations.   
It should be noted that our study used polarized, differentiated epithelial cell layer grown at 
air-liquid interface, and although a number of previous reports studied intracellular delivery 
of self-assembled protein carrying systems, these are conducted on a variety of non-polarized 
cells, such as HeLa and dendritic cells [53, 54], which makes direct comparisons difficult.  
Aiming at developing inhalable formulations, we spray-dried PEG-poly(GA)-protein 
complexes using a ‘standard’ process and excipients. In these formulations, trehalose was 
selected as the matrix excipient due to its well characterized ability to stabilize biologics. 
When spray dried, trehalose creates an amorphous matrix that forms hydrogen bonds with 
biologic materials and protects structural integrity following the removal of water. Other 
excipients that are approved for inhalation formulations, such as mannitol and lactose, are 
known to crystallize when spray dried, limiting their ability to provide a protective amorphous 
matrix. The amorphous nature of trehalose renders the particles hygroscopic and highly 
cohesive. This limits the ability of passive inhalers to efficiently disperse the powder to a 
respirable size (<5 µm aerodynamic diameter) for lung delivery. Leucine is a surface active 
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amino acid that accumulates at the surface of the droplet during the spray drying process. 
This results in high concentrations of leucine localized to the particle surface in comparison 
to the particle interior. This deposition changes the properties of the spray dried particle, 
decreasing cohesion and therefore reducing the energy required to efficiently disperse the 
powder to a respirable size during inhalation. The addition of leucine dramatically improves 
the fine particle fraction achievable from the device, directly translating into improved 
deposition properties of the powder [24]. The resulting formulations possessed aerodynamic 
properties suitable for inhalable product, with particle size (D50) < 5 µm (Supporting 
information, Table S1). 10% loading level was selected to ensure stability of the nano-
complexes during the spray drying process and to maintain efficient aerosol performance. In 
this instance, the powders exhibited comparable aerosol performance when formulated as 
the placebo formulation (trehalose and leucine) and as the nano-complex loaded powder 
(loaded at 10% level), indicating that inclusion of the nano-complexes did not change the 
particle properties. These formulations were shown to maintain lysozyme biological activity 
[24]. They were applied as dry powders to Calu-3 cell layers grown at air-liquid interface, and 
in in vivo studies, by Penn-Century® insufflator device. Particle morphology, size and size 
distribution prior and following spraying by the insufflator are shown in Figure 7 (and 
Supporting Information, Tables S1, S2 and Figure S14). SEM images in Figure 7 illustrate 
spherical particle shape of dry powders prior and following spraying with insufflator device 
for formulations prepared with PEG-poly(GA)-lysozyme complexes. Interestingly, some loss 
of spherical morphology for powders containing ‘free’ lysozyme is seen, indicating in turn that 
complexation of the protein with PEG-poly(GA) provided a level of structural stabilization of 




Figure 7. Scanning electron microscopy images of PEG-poly(GA)-lysozyme complexes formulated as dry powders 
by spray drying. Upper row A) dry powder formulations prior spraying and lower row B) following spraying of 
formulated dry powders through a Penn-Century® insufflator device. All dry powders contain 6.6% (w/w) 
phosphate salts, 10% (w/w) leucine and up to 100% (w/w) trehalose. Image for free lysozyme after spraying 
through Penn-Century® insufflator is presented at enlarged scale to emphasize morphology change.  
 
In line with the results obtained for cells treatment with suspensions of PEG-poly(GA)-protein 
complexes (Figure 6), application of respective dry powders demonstrates a significantly 
higher cellular internalization of targeted [B12-PEG3k-poly(GA)]-Cy5-lysozyme complexes, 
relative to ‘free’ lysozyme, or non-targeted complexes (Figure 8).  The results hence indicate 
that i) B12-targeted PEG-poly(GA)-lysozyme complexes can be formulated into dry powders 
by spray drying process, ii) the complexation somewhat protects the powder morphology on 
subsequent exposure to spraying, and iii) B12-targeted complexes are released from dry 
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Figure 8. Cellular internalization of B12-targeted and non-targeted PEG-poly(GA):Cy5-lysozyme complexes 
formulated into dry powders in in vitro Calu-3 epithelial model. Samples were applied as dry powders using dry 
powder insufflator (PenCentury insufflator) directly onto apical side of the Calu-3 cells grown as polarized layers 
on Transwell supports under air-liquid interface conditions (Supporting information, Figure S13). ‘Free 
lysozyme’ denotes dry powder formulated from Cy5-lysozyme in the absence of complexing polymers. All dry 
powders contain phosphate buffer salts (6.6 % w/w), leucine (10 % w/w) and trehalose (up to 100 % w/w). One-
way ANOVA was used for statistical analysis. *** p < 0.001, **** p < 0.0001. 
 
Local pulmonary tolerance of polymer-protein complexes-based dry powder formulations 
in healthy mice. The safety profile of PEG-poly(GA)-lysozyme complexes formulated as dry 
powder inhalable formulations was investigated in healthy mice. Previous reports have shown 
that administration of polymer-based pulmonary formulations can induce inflammatory 
responses [55, 56], whilst the presence in dry powder formulations of poorly soluble material 
has been shown to induce local irritation and pro-inflammatory effect in the respiratory tract 
[57, 58]. In addition, the delivery of proteins to the lungs has been shown to induce 
immunogenicity, local irritation and toxicity [59-61]. In this work, we evaluated the lung 
tolerance profile of PEG-poly(GA)-lysozyme dry powders in healthy BALB/c mice, by 
quantifying cell count and local concentration of IL-1β, IL-6 and TNF-α cytokine in 
bronchoalveolar lavage fluids after endotracheal administrations of 2 mg of dry powders 3 
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times per week, for 3 weeks period. The dose and the administration schedules were 
established taking into account limitations of the preclinical mice model. Aimed, and 
achieved, administration of 2 mg (Supporting information, Table S1), corresponds to a dose 
of ~100 mg/kg of powder mass and ~10 mg/kg protein – within a range potentially  expected  
of a therapeutic protein to be delivered in humans. The administration schedule was devised 
taking into account limitations associated with general anaesthesia of mice during 
endotracheal instillation and their well-being. 48 hours (i.e. three doses per week) was 
previously assessed as the minimum interval between two such administration procedures 
[62, 63]. Systems tested included: dry powder formulation of [mPEG2k-lin-GA30/B12-PEG3k-
lin-(GA24)]-lysozyme targeted complexes (UDP-TC), formulation containing only dry powder 
excipients (UDP), and system containing ‘free’ lysozyme formulated with dry powder 
excipients but with no polymers to complex the protein (UDP-P) (the compositions of these 
formulations are shown in Table 1).  
Firstly, the potential inflammatory response of these formulations was investigated by 
quantification of the concentration of IL-1β, IL-6, and TNF-α pro-inflammatory cytokines [64, 
65], in the epithelial lining fluid of the lungs. Mice treated with lipopolysaccharide (LPS) - outer 
membrane component of Gram-negative bacteria known as a strong stimulator of innate or 
natural immunity [66] - were used as a positive control group. As expected, a significant 
increase in IL-1β, IL-6, and TNF-α level was observed on LPS treatment, compared to 
untreated mice (Figure 9). The levels of measured cytokines did not increase significantly 
above the negative control level (untreated mice group) following administration of dry 
powder formulations. The data hence clearly illustrate that on a repeated, prolonged 




























































































































































Figure 9. Pro-inflammatory cytokine IL-1β, IL-6, and TNF-α gene expression in lung tissues following 
administration of 2 mg of dry powder formulations 3 times a week for 3 weeks. Mice groups were untreated 
(negative control) or treated with LPS (positive control), treated with a formulation containing only dry powder 
excipients (UDP), free lysozyme formulation containing lysozyme and dry powder excipients (UDP-P), and dry 
powder formulation containing targeted complexes (UDP-TC) - with 85:15 [mPEG2k-lin-GA30/B12-PEG3k-lin-
(GA24)]-lysozyme composition. One-way ANOVA was used for statistical analysis. *** p < 0.001, **** p < 0.0001. 
 
To further investigate the tolerability of the designed dry powder formulations upon 
pulmonary administration, the differential cell count of alveolar macrophages (AM), 
polymorphonuclear neutrophils (PMN), and lymphocytes (LM) was also performed (Figure 
11). Following single administration of 1 µg LPS, the number of AM dramatically decreased to 
around 50% relative to untreated mice, whereas the percentage of PMN significantly 
increased, clearly indicating a pro-inflammatory reaction. On the contrary, all the dry powder 
formulations had values for AM, PMN and LM at the level similar to untreated mice control. 
This was qualitatively confirmed by optical microscopy observations (Figure 10). These 
experiments thus suggest that, under the conditions investigated, B12-PEG-poly(GA)-lysozyme 
complexes-based dry powder formulations are well tolerated in the lungs following 




Figure 10. Bronchoalveolar lavage fluid analysis following a single administration of dry powder formulations. 
Differential cell count and representative images of different cells found in the bronchoalveolar lavage fluid. 
Mice groups were not treated ((negative control) or treated with single administration of 1 µg LPS (positive 
control), and 2 mg of dry powder formulation containing formulation excipients  (UDP),  free lysozyme dry 
powder formulation (UDP-P), or dry powder formulation containing targeted complexes (UDP-TC) [with 
composition of 85:15 mPEG2k-lin-GA30/B12-PEG3k-lin-(GA24)]-lysozymes] 3 times a week for 3 weeks. One-way 
ANOVA was used for statistical analysis. *** p < 0.001, **** p < 0.0001. 
 
In vivo pulmonary deposition and retention of polymer-protein complexes-based dry 
powder formulations in healthy mice. Pulmonary delivery of particle formulations can be 
challenging, due to different particle clearance mechanisms present at various levels of the 
airway path in the lungs, such as the mucociliary escalator, proteolytic degradation and 
macrophage capture [67]. However, a design of drug delivery system can potentially 
overcome these removal mechanisms [67] and, by prolonging the time of exposure of lung 
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tissue to relevant protein therapeutics, enhance their therapeutic effects. In this part of our 
study, the ability of PEG3k-(GA24)-lysozyme complexes to increase the retention of proteins in 
the lungs was assessed.   
Accordingly, a 2 mg dose of dry powder formulation (Supporting information, Table S2, 
Figure S14) was administered to healthy mice by the endotracheal route, using a Penn-
Century insufflator. Figure 11 shows the lung distribution of Cy5-labelled lysozyme following 
administration of dry powder formulation containing free Cy5-labelled lysozyme (LDP-P), dry 
powder formulation containing non-targeted mPEG2k-lin-(GA30)-labelled lysozyme complexes 
(LDP-NT), and dry powder formulation containing 85:15 [mPEG2k-lin-GA30/B12-PEG3k-lin-
(GA24)]-lysozyme targeted complexes (LDP-TC). Five non-serial cryo-sections of 7 µm 
thickness per lung were prepared, imaged by fluorescence microscopy (Supporting 
Information, Figure S15), and representative examples are shown in Figure 11. Images depict 
that immediately following administration (at t=0 h) Cy5-lysozyme powders were indeed 
deposited in the lungs, which agrees with the previous studies reporting that dry powders 
with good dispersion properties can be deposited in the respiratory zone in the mouse lungs 
[68]. Fluorescent images obtained from different lung tissue sections however indicate that 
the deposition was not homogeneous throughout the lung (Supporting Information Figure 
S15), which increases complexity in making comparisons between the systems tested. This 
non-homogeneous deposition pattern have also been observed in other studies [63, 69, 70]. 
However, analysis of the images (Figure 11, graph) indicates that in different samples imaged 
at 14 hours after the administration of dry powders the fluorescence arising from Cy5-
lysozyme is higher, relative to nuclear DAPI staining, for targeted complexes formulations 
(LDP-TC) in comparison to formulations containing ‘free’ (LDP-P) and non-targeted Cy5-
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lysozyme complexes (LDP-NT). This would indicate lengthier protein lung retention for the 
targeted formulation. All data considered, the lung deposition experiment provides an initial 
evidence of prolonged protein retention following administration of vitamin B12-targeted 
complexes. Further studies are needed to confirm if this prolonged retention is indeed a 
consequence of the increased cellular internalization of targeted complexes seen in the in 
vitro cell culture experiment, and if this would lead to a potentially improved therapeutic 
effect of such delivered protein in the lung. Nevertheless, the in vivo deposition experiment 
suggests that targeted polymer-protein complexes can influence and potentially extend 
retention time of the protein cargo in the lungs.  
 
Figure 11. Distribution of fluorescent labelled protein in the lung tissue of healthy mice following endotracheal 
application using the pulmonary delivery device of 2 mg dry powder formulations at different times after 
administration (in hours). Examples of a 7-µm longitudinal, non-consecutive lung cryo-sections imaged using a 
fluorescent microscope at 200 x magnification are shown (also in Supporting Information Figure S15). The 
images show the distribution of red labelled lysozyme-Cy5 (‘Cy5 protein’), blue nuclear stain (‘DAPI’) and merged 
images (‘Merged’); LDP-TC denotes dry powder formulation of [85:15 mPEG2k-lin-GA30/B12-PEG3k-lin-(GA24)]-
lysozyme complexes), LDP-NT drug powder formulation of [mPEG2k-lin-GA30]-lysozyme non-targeted complexes, 
and LDP-P denotes free protein dry powder (without complexing polymers) formulation. Graph shows calculated 
ratio of Cy5 to DAPI emission intensity, obtained by analysis of images from 5 non-serial, random cryo-sections 
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per lung (adopted from Dawson et al [28]). Low ratio for LDP-TC at 0 h illustrates the effect of non-homogeneous 
lung deposition on material present in the cryo-sections prepared for in the analysis.   
 
Conclusions 
In this study, we assessed the potential of vitamin B12 ligand-targeted poly(ethylene glycol)-
block-poly(glutamic acid) copolymers to self-assemble with a protein cargo into polymer-
protein complexes, with the aim to design an inhalation product with prolonged lung 
retention and intracellular delivery of protein to the lung epithelium. Our study shows that 
PEG-poly(GA)-protein complexes did not trigger significant complement activation, nor did 
they induce an increased production of pro-inflammatory cytokines in a chronic, repeated 
administration study in heathy mice. Furthermore, no changes in cell count of alveolar 
macrophages, polymorphonuclear neutrophils and lymphocytes, relative to untreated 
control, were observed that would indicate development of an inflammation process in the 
lung. Hence, toxicity data demonstrate that PEG-poly(GA) polymers based formulations are 
well tolerated in the lungs following chronic treatment, with no significant toxicity or lung 
inflammation indications.  
The data demonstrate a B12-receptor mediated internalization of B12 ligand-targeted PEG-
poly(GA)-protein complexes in vitro in differentiated, polarized Calu-3 cells epithelial model. 
When fabricated into dry powders for inhalation using a standard spray drying procedure, 
and applied in vivo, the deposition data show prolonged lung retention of the protein cargo 
at 14 hours after administration for targeted B12-PEG-poly(GA)-protein complexes, relative to 
non-targeted or ‘free’ protein formulations. Taken together the results presented in this study 
show that vitamin B12-PEG-poly(GA) copolymers have a potential as a new class of targeted 






Vectura Group plc and the School of Pharmacy at the University of Nottingham are 
acknowledged for funding Alejandro Nieto-Orellana and Huitong Li’s PhD studentships. The 
authors would like to thank Dr. Ruggero Foralosso for providing insight and expertise that 
assisted the research.  
Data created during this research are openly available from the corresponding authors 
(snjezana.stolnik@nottingham.ac.uk and giuseppe.mantovani@nottingham.ac.uk) and at the 
University of Nottingham Research Data Management Repository 
(https://rdmc.nottingham.ac.uk/), and data supporting this study are provided as 





[1] J.S. Patil, S. Sarasija, Pulmonary drug delivery strategies: A concise, systematic review, Lung 
India : Official Organ of Indian Chest Society, 29 (2012) 44-49. 
[2] S. Rohatagi, F. Calic, N. Harding, M.L. Ozoux, J.P. Bouriot, S. Kirkesseli, L. DeLeij, B.K. Jensen, 
Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after 
single and repeated administration in healthy male and female subjects and asthmatic 
patients, J. Clin. Pharmacol., 40 (2000) 1211-1226. 
[3] O. Merimsky, E. Gez, R. Weitzen, H. Nehushtan, R. Rubinov, H. Hayat, T. Peretz, M. Ben-
Shahar, H. Biran, R. Katsenelson, V. Mermershtein, D. Loven, N. Karminsky, A. Neumann, D. 
Matcejevsky, M. Inbar, Targeting pulmonary metastases of renal cell carcinoma by inhalation 
of interleukin-2, Ann. Oncol., 15 (2004) 610-612. 
[4] D.C. Klonoff, Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the 
market has favorable properties, J. Diabetes Sci. Technol., 8 (2014) 1071-1073. 
[5] M.P. Baker, H.M. Reynolds, B. Lumicisi, C.J. Bryson, Immunogenicity of protein 
therapeutics: The key causes, consequences and challenges, Self Nonself, 1 (2010) 314-322. 
[6] A. Hussain, J.J. Arnold, M.A. Khan, F. Ahsan, Absorption enhancers in pulmonary protein 
delivery, J. Controlled Release, 94 (2004) 15-24. 
36 
 
[7] A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, F.F. Davis, Effect of covalent attachment 
of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. 
Chem., 252 (1977) 3582-3586. 
[8] P.L. Turecek, M.J. Bossard, F. Schoetens, I.A. Ivens, PEGylation of Biopharmaceuticals: A 
Review of Chemistry and Nonclinical Safety Information of Approved Drugs, J. Pharm. Sci., 
105 (2016) 460-475. 
[9] Y.S. Youn, J.E. Jeon, S.Y. Chae, S. Lee, K.C. Lee, PEGylation improves the hypoglycaemic 
efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice, 
Diabetes Obes. Metab., 10 (2008) 343-346. 
[10] T.H. Kim, C.W. Park, H.Y. Kim, M.H. Chi, S.K. Lee, Y.M. Song, H.H. Jiang, S.M. Lim, Y.S. 
Youn, K.C. Lee, Low molecular weight (1 kDa) polyethylene glycol conjugation markedly 
enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic 
db/db mice, Biol. Pharm. Bull., 35 (2012) 1076-1083. 
[11] M.A. Croyle, A. Patel, K.N. Tran, M. Gray, Y. Zhang, J.E. Strong, H. Feldmann, G.P. 
Kobinger, Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to 
the vaccine carrier and improves the immune response in mice, PLoS One, 3 (2008) e3548. 
[12] M.N. Sahib, Y. Darwis, K.K. Peh, S.A. Abdulameer, Y.T. Tan, Rehydrated sterically stabilized 
phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization 
and in vitro, in vivo evaluations, International journal of nanomedicine, 6 (2011) 2351-2366. 
[13] K. Kataoka, T. Matsumoto, M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, 
G.S. Kwon, Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) 
copolymer micelles: their pharmaceutical characteristics and biological significance, J. 
Control. Release, 64 (2000) 143-153. 
[14] J.K. Dozier, M.D. Distefano, Site-Specific PEGylation of Therapeutic Proteins, Int. J. Mol. 
Sci., 16 (2015) 25831-25864. 
[15] A. Kato, S. Tanimoto, Y. Muraki, K. Kobayashi, I. Kumagai, Structural and functional 
properties of hen egg-white lysozyme deamidated by protein engineering, Biosci. Biotechnol. 
Biochem., 56 (1992) 1424-1428. 
[16] J.A. Rodriguez-Martinez, R.J. Sola, B. Castillo, H.R. Cintron-Colon, I. Rivera-Rivera, G. 
Barletta, K. Griebenow, Stabilization of alpha-chymotrypsin upon PEGylation correlates with 
reduced structural dynamics, Biotechnol. Bioeng., 101 (2008) 1142-1149. 
[17] A. Harada, K. Kataoka, Novel Polyion Complex Micelles Entrapping Enzyme Molecules in 
the Core:  Preparation of Narrowly-Distributed Micelles from Lysozyme and Poly(ethylene 
glycol)−Poly(aspartic acid) Block Copolymer in Aqueous Medium, Macromolecules, 31 (1998) 
288-294. 
[18] D. Tsiourvas, Z. Sideratou, N. Sterioti, A. Papadopoulos, G. Nounesis, C.M. Paleos, Insulin 
complexes with PEGylated basic oligopeptides, J. Colloid Interface Sci., 384 (2012) 61-72. 
[19] S. Salmaso, S. Bersani, F. Mastrotto, G. Tonon, R. Schrepfer, S. Genovese, P. Caliceti, Self‐
assembling nanocomposites for protein delivery: Supramolecular interactions between PEG‐
cholane and rh‐G‐CSF, J. Controlled Release, 162 (2012) 176-184. 
[20] E. Ambrosio, M. Barattin, S. Bersani, S. Shubber, S. Uddin, C.F. van der Walle, P. Caliceti, 
S. Salmaso, A novel combined strategy for the physical PEGylation of polypeptides, J. 
Controlled Release, 226 (2016) 35-46. 
[21] S. Salmaso, S. Bersani, A. Scomparin, A. Balasso, C. Brazzale, M. Barattin, P. Caliceti, A 




[22] C.I. Grainger, L.L. Greenwell, D.J. Lockley, G.P. Martin, B. Forbes, Culture of Calu-3 cells 
at the air interface provides a representative model of the airway epithelial barrier, Pharm. 
Res., 23 (2006) 1482-1490. 
[23] A. Nieto-Orellana, M. Di Antonio, C. Conte, F.H. Falcone, C. Bosquillon, N. Childerhouse, 
G. Mantovani, S. Stolnik, Effect of polymer topology on non-covalent polymer-protein 
complexation: miktoarm versus linear mPEG-poly(glutamic acid) copolymers, Polymer 
Chemistry, 8 (2017) 2210-2220. 
[24] A. Nieto-Orellana, D. Coghlan, M. Rothery, F.H. Falcone, C. Bosquillon, N. Childerhouse, 
G. Mantovani, S. Stolnik, Dry-powder formulations of non-covalent protein complexes with 
linear or miktoarm copolymers for pulmonary delivery, Int. J. Pharm., 540 (2018) 78-88. 
[25] E. Cingolani, S. Alqahtani, R.C. Sadler, D. Prime, S. Stolnik, C. Bosquillon, In vitro 
investigation on the impact of airway mucus on drug dissolution and absorption at the air-
epithelium interface in the lungs, Eur. J. Pharm. Biopharm., 141 (2019) 210-220. 
[26] M. Bivas-Benita, R. Zwier, H.E. Junginger, G. Borchard, Non-invasive pulmonary aerosol 
delivery in mice by the endotracheal route, Eur. J. Pharm. Biopharm., 61 (2005) 214-218. 
[27] R. Rosiere, M. Van Woensel, V. Mathieu, I. Langer, T. Mathivet, M. Vermeersch, K. Amighi, 
N. Wauthoz, Development and evaluation of well-tolerated and tumor-penetrating polymeric 
micelle-based dry powders for inhaled anti-cancer chemotherapy, Int. J. Pharm., 501 (2016) 
148-159. 
[28] M.R. Dawson, D.G. Duda, S.S. Chae, D. Fukumura, R.K. Jain, VEGFR1 activity modulates 
myeloid cell infiltration in growing lung metastases but is not required for spontaneous 
metastasis formation, PLoS One, 4 (2009) e6525. 
[29] G.J. Russell-Jones, S.W. Westwood, A.D. Habberfield, Vitamin B12 mediated oral delivery 
systems for granulocyte-colony stimulating factor and erythropoietin, Bioconjug. Chem., 6 
(1995) 459-465. 
[30] P. Tuma, A.L. Hubbard, Transcytosis: crossing cellular barriers, Physiol. Rev., 83 (2003) 
871-932. 
[31] R. Fowler, D. Vllasaliu, F.H. Falcone, M. Garnett, B. Smith, H. Horsley, C. Alexander, S. 
Stolnik, Uptake and transport of B(12)-conjugated nanoparticles in airway epithelium, J. 
Controlled Release, 172 (2013) 374-381. 
[32] R. Fowler, D. Vllasaliu, F.F. Trillo, M. Garnett, C. Alexander, H. Horsley, B. Smith, I. 
Whitcombe, M. Eaton, S. Stolnik, Nanoparticle transport in epithelial cells: pathway switching 
through bioconjugation, Small, 9 (2013) 3282-3294. 
[33] A.O. Saeed, J.P. Magnusson, E. Moradi, M. Soliman, W. Wang, S. Stolnik, K.J. Thurecht, 
S.M. Howdle, C. Alexander, Modular construction of multifunctional bioresponsive cell-
targeted nanoparticles for gene delivery, Bioconjug. Chem., 22 (2011) 156-168. 
[34] C.J. Dix, I.F. Hassan, H.Y. Obray, R. Shah, G. Wilson, The transport of vitamin B12 through 
polarized monolayers of Caco-2 cells, Gastroenterology, 98 (1990) 1272-1279. 
[35] K.S. Ramanujam, S. Seetharam, M. Ramasamy, B. Seetharam, Expression of cobalamin 
transport proteins and cobalamin transcytosis by colon adenocarcinoma cells, Am. J. Physiol., 
260 (1991) G416-422. 
[36] G.J. Russell-Jones, L. Arthur, H. Walker, Vitamin B12-mediated transport of nanoparticles 
across Caco-2 cells, Int. J. Pharm., 179 (1999) 247-255. 
[37] K.B. Chalasani, G.J. Russell-Jones, A.K. Jain, P.V. Diwan, S.K. Jain, Effective oral delivery of 
insulin in animal models using vitamin B12-coated dextran nanoparticles, J. Control. Release, 
122 (2007) 141-150. 
38 
 
[38] R. Kozyraki, O. Cases, Vitamin B12 absorption: Mammalian physiology and acquired and 
inherited disorders, Biochimie, 95 (2013) 1002-1007. 
[39] R. Green, L.H. Allen, A.-L. Bjørke-Monsen, A. Brito, J.-L. Guéant, J.W. Miller, A.M. Molloy, 
E. Nexo, S. Stabler, B.-H. Toh, P.M. Ueland, C. Yajnik, Vitamin B12 deficiency, Nature Reviews 
Disease Primers, 3 (2017) 17040. 
[40] C. Gherasim, M. Lofgren, R. Banerjee, Navigating the B12 Road: Assimilation, Delivery, 
and Disorders of Cobalamin, J. Biol. Chem., 288 (2013) 13186-13193. 
[41] C.R. Benoit, A.E. Stanton, A.C. Tartanian, A.R. Motzer, D.M. McGaughey, S.R. Bond, L.C. 
Brody, Functional and phylogenetic characterization of noncanonical vitamin B12–binding 
proteins in zebrafish suggests involvement in cobalamin transport, J. Biol. Chem., 293 (2018) 
17606-17621. 
[42] S. Bose, S. Seetharam, N.M. Dahms, B. Seetharam, Bipolar functional expression of 
transcobalamin II receptor in human intestinal epithelial Caco-2 cells, J. Biol. Chem., 272 
(1997) 3538-3543. 
[43] O. Aseem, J.L. Barth, S.C. Klatt, B.T. Smith, W.S. Argraves, Cubilin expression is monoallelic 
and epigenetically augmented via PPARs, BMC Genomics, 14 (2013) 405. 
[44] R. Respaud, L. Vecellio, P. Diot, N. Heuzé-Vourc’h, Nebulization as a delivery method for 
mAbs in respiratory diseases, Expert Opinion on Drug Delivery, 12 (2015) 1027-1039. 
[45] P.J. Borm, W. Kreyling, Toxicological hazards of inhaled nanoparticles--potential 
implications for drug delivery, Journal of nanoscience and nanotechnology, 4 (2004) 521-531. 
[46] K. Donaldson, V. Stone, C.L. Tran, W. Kreyling, P.J. Borm, Nanotoxicology, Occup. Environ. 
Med., 61 (2004) 727-728. 
[47] P.H. Pandya, D.S. Wilkes, Complement system in lung disease, Am. J. Respir. Cell Mol. 
Biol., 51 (2014) 467-473. 
[48] D. Filpula, H. Zhao, Releasable PEGylation of proteins with customized linkers, Adv. Drug 
Del. Rev., 60 (2008) 29-49. 
[49] M. Takano, Y. Koyama, H. Nishikawa, T. Murakami, R. Yumoto, Segment-selective 
absorption of lysozyme in the intestine, Eur. J. Pharmacol., 502 (2004) 149-155. 
[50] E.V. Seliverstova, N.P. Prutskova, Receptor-mediated endocytosis of lysozyme in renal 
proximal tubules of the frog Rana temporaria, Eur. J. Histochem., 59 (2015) 2482. 
[51] F. Meng, G.H. Engbers, J. Feijen, Polyethylene glycol-grafted polystyrene particles, J. 
Biomed. Mater. Res. A, 70 (2004) 49-58. 
[52] A. Alshehri, A. Grabowska, S. Stolnik, Pathways of cellular internalisation of liposomes 
delivered siRNA and effects on siRNA engagement with target mRNA and silencing in cancer 
cells, Sci. Rep., 8 (2018) 3748. 
[53] H. Ayame, N. Morimoto, K. Akiyoshi, Self-Assembled Cationic Nanogels for Intracellular 
Protein Delivery, Bioconjugate Chem., 19 (2008) 882-890. 
[54] S. De Koker, B.G. De Geest, C. Cuvelier, L. Ferdinande, W. Deckers, W.E. Hennink, S.C. 
De Smedt, N. Mertens, In vivo Cellular Uptake, Degradation, and Biocompatibility of 
Polyelectrolyte Microcapsules, Adv. Funct. Mater., 17 (2007) 3754-3763. 
[55] A. Beyerle, A. Braun, A. Banerjee, N. Ercal, O. Eickelberg, T.H. Kissel, T. Stoeger, 
Inflammatory responses to pulmonary application of PEI-based siRNA nanocarriers in mice, 
Biomaterials, 32 (2011) 8694-8701. 
[56] H.P. Patil, D. Freches, L. Karmani, G.A. Duncan, B. Ucakar, J.S. Suk, J. Hanes, B. Gallez, R. 
Vanbever, Fate of PEGylated antibody fragments following delivery to the lungs: Influence of 
delivery site, PEG size and lung inflammation, J. Controlled Release, 272 (2018) 62-71. 
39 
 
[57] M.C. Jones, S.A. Jones, Y. Riffo-Vasquez, D. Spina, E. Hoffman, A. Morgan, A. Patel, C. 
Page, B. Forbes, L.A. Dailey, Quantitative assessment of nanoparticle surface hydrophobicity 
and its influence on pulmonary biocompatibility, J. Control. Release, 183 (2014) 94-104. 
[58] A. Kumar, L.A. Dailey, B. Forbes, Lost in translation: what is stopping inhaled 
nanomedicines from realizing their potential?, Ther. Deliv., 5 (2014) 757-761. 
[59] A. Yamamoto, S. Okumura, Y. Fukuda, M. Fukui, K. Takahashi, S. Muranishi, Improvement 
of the pulmonary absorption of (Asu1,7)-eel calcitonin by various absorption enhancers and 
their pulmonary toxicity in rats, J. Pharm. Sci., 86 (1997) 1144-1147. 
[60] R.U. Agu, M.I. Ugwoke, M. Armand, R. Kinget, N. Verbeke, The lung as a route for systemic 
delivery of therapeutic proteins and peptides, Respir. Res., 2 (2001) 198-209. 
[61] L. Heinemann, W. Klappoth, K. Rave, B. Hompesch, R. Linkeschowa, T. Heise, Intra-
individual variability of the metabolic effect of inhaled insulin together with an absorption 
enhancer, Diabetes Care, 23 (2000) 1343-1347. 
[62] M. Morello, C.L. Krone, S. Dickerson, E. Howerth, W.A. Germishuizen, Y.L. Wong, D. 
Edwards, B.R. Bloom, M.K. Hondalus, Dry-powder pulmonary insufflation in the mouse for 
application to vaccine or drug studies, Tuberculosis, 89 (2009) 371-377. 
[63] N. Wauthoz, P. Deleuze, J. Hecq, I. Roland, S. Saussez, I. Adanja, O. Debeir, C. 
Decaestecker, V. Mathieu, R. Kiss, K. Amighi, In vivo assessment of temozolomide local 
delivery for lung cancer inhalation therapy, Eur. J. Pharm. Sci., 39 (2010) 402-411. 
[64] C. Gabay, Interleukin-6 and chronic inflammation, Arthritis Res. Ther., 8 (2006) S3-S3. 
[65] K. Ren, R. Torres, Role of interleukin-1beta during pain and inflammation, Brain Res. Rev., 
60 (2009) 57-64. 
[66] C. Alexander, E.T. Rietschel, Bacterial lipopolysaccharides and innate immunity, J. 
Endotoxin Res., 7 (2001) 167-202. 
[67] I.M. El-Sherbiny, N.M. El-Baz, M.H. Yacoub, Inhaled nano- and microparticles for drug 
delivery, Global Cardiology Science & Practice, 2015 (2015) 2. 
[68] C. Duret, N. Wauthoz, R. Merlos, J. Goole, C. Maris, I. Roland, T. Sebti, F. Vanderbist, K. 
Amighi, In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use 
in dose-dependent preclinical studies in mice, Eur. J. Pharm. Biopharm., 81 (2012) 627-634. 
[69] V. Capel, D. Vllasaliu, P. Watts, P.A. Clarke, D. Luxton, A.M. Grabowska, G. Mantovani, S. 
Stolnik, Water-soluble substituted chitosan derivatives as technology platform for inhalation 
delivery of siRNA, Drug Deliv., 25 (2018) 644-653. 
[70] D. Li, Y. Li, G. Li, Y. Zhang, J. Li, H. Chen, Fluorescent reconstitution on deposition of PM2.5 
























Targeted PEG-poly(glutamic acid) complexes for 
inhalation protein delivery to the lung  
 
A. Nieto-Orellana,a, 1 H. Li,a, 1 R. Rosiere,b N. Wauthoz,b H. Williams,c C. J. Monteiro,a C. Bosquillon,a N. 
Childerhouse,d G. Keegan,d D. Coghlan,d G. Mantovani a,* and S. Stolnik a,* 
 
aMolecular Therapeutics and Formulation Division, School of Pharmacy, University of Nottingham, Nottingham, 
UK; bLaboratory of Pharmaceutics and Biopharmaceutics (ULBGAL), Université Libre de Bruxelles, Bruxelles, BE; 
cCentre for Biomolecular Sciences, University of Nottingham, Nottingham, UK; dVectura Group plc, Chippenham, 
UK.  1 These authors contributed equally to this paper 
 
* Corresponding authors.  
Contents 
Materials ........................................................................................................... 42 
Instrumentation ................................................................................................ 43 
Synthesis of polymers and intermediates. ....................................................... 45 
Synthesis of cyanocobalamin fluorescent probe pyr-B12. ................................ 56 
Synthesis of Lysozyme-Cyanine 5 (Lysozyme-Cy5) ........................................... 62 
Dry powders: Particle size distribution on Transwell® inserts .......................... 62 
41 
 
NMR spectra ..................................................................................................... 67 






3,4,5-tris(allyloxy)benzoic acid,[23] γ-benzyl-L-glutamate N-carboxyanhydride,[23] and 2-(2-
(2-azidoethoxy)ethoxy)ethanol[71] were prepared as described previously. L-Glutamic acid γ-
benzyl ester (≥99.0%), allyl bromide (97%), cysteamine hydrochloride (≥98%), 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), p-toluenesulfonyl 
chloride (≥99.0%), trimethylamine (≥ 99.0 %), sodium bicarbonate, sodium azide (≥99.0%), 
cyanocobalamin (vitamin B12, ≥98.0%), 1,1′-carbonyldiimidazole (CDI), dibenzocyclooctyne-
amine, sodium phosphate dibasic (99.9%), sodium phosphate monobasic dehydrate (≥99.0%), 
L-leucine, D-(+)-trehalose dehydrate, 1-butanol, 1M ammonium hydroxide solution, 
acetonitrile (anhydrous, 99.8%), dichloromethane (anhydrous, ≥99.8%), tetrahydrofuran 
(THF, anhydrous, ≥99.9%), methanol (MeOH, anhydrous, 99.8%), dimethyl sulfoxide (DMSO, 
anhydrous, ≥99.9%), deuterated chloroform (CDCl3, 99.8 atom % D), deuterium oxide (D2O, 
99.9 atom % D), deuterated methanol (CD3OD, 99.8 atom % D), Dulbecco’s Minimal Eagle 
Medium: Nutrient mixture F-12 (DMEM/F12), foetal bovine serum (10%), L-glutamine (200 
mM), antibiotic solution (100 U mL-1 penicillin and 0.1 mg mL-1 streptomycin), non-essential 
aminoacids (100%), trypsin/EDTA solution, DPBS and Hanks’ Balanced Salts (HBSS) were 
purchased from Sigma Aldrich. Methyl 3,4,5-trihydroxybenzoate (98.0%), potassium 
carbonate anhydrous (≥99.0%), sodium hydroxide (≥97.0%), 2,2-dimethoxy-2-
phenylacetophenone (DPAP) (99.0%), hydrochloric acid, magnesium sulfate dried, toluene, 
methanol, diethyl ether anhydrous, propan-2-ol and petroleum ether were supplied by Fisher 
Scientific. Triphosgene 98.0% and lysozyme molecular biology grade were purchased from 
Alfa Aesar and AppliChem, respectively. O-(2-aminoethyl)polyethylene glycol 3.0 kDa and 
cyanine 5 NHS ester were supplied by Iris Biotech and Lumiprobe, respectively. All the 
chemicals were used as received without further purification. Anhydrous solvents were used 
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as received and stored under dry and inert atmosphere. Thin layer chromatography (TLC) was 
carried out on pre-coated TLC sheets ALUGRAM®SIL G/UV254 purchased from Macherey-
Nagel. TLCs were visualized by exposure to UV light (254 nm) followed by staining with 
KMnO4. Calu-3 cells were purchased from the American Type Culture Collection (ATCC® HTB-
55™). Phosphate buffer saline tablets were obtained from Oxoid (Basingstoke, UK). CellTiter 
96® aqueous one solution cell proliferation assay (MTS) was supplied by Promega UK 
(Southampton, UK). Sheep erythrocytes and rabbit anti-sheep erythrocytes were purchased 
from Eurobio (Les Ulis, France).  
2. Instrumentation  
Nuclear Magnetic Resonance (NMR) Spectroscopy. 1D 1H and 13C NMR spectra were 
recorded on a Bruker DPX 400 MHz. Analysis of spectra was done using MestRENova 6.0.2, 
Mestrelab Research S.L. All chemical shifts are reported in ppm (δ), using residual solvent as 
an internal standard (CDCl3: δH 7.26, δC 77.16; D2O: δH 4.79; CD3OD: δH 3.31). The following 
abbreviations were used to explain the multiplicities: bd=broad singlet, s=singlet, d=doublet, 
t=triplet, m=multiplet. 2D HSQC NMR spectra were recorded on a 800 MHz Avance III 
spectrometer equipped with a 5mm QCI cryoprobe. 
Electrospray ionization mass spectrometry (ESI-MS). Mass spectra were recorded on a 
Micromass LCT KC453 spectrometer by electrospray (ES+). Samples were analyzed as solutions 
in acetonitrile, water and formic acid. 
Fourier Transform Infrared Spectroscopy (FT-IR) was performed on Thermo Scientific Nicolet 
IR 200 FT-IR and spectra were analyzed using Omnic 8.0 1992-2008 Thermo Fisher Scientific 




Size exclusion chromatography (SEC). Aqueous SEC was performed on a Shimadzu UPLC 
system fitted with a differential refractive index detector. The mobile phase was aqueous 0.10 
M NaNO3, 0.02 (w/v) NaN3, pH 10.0 at 35°C and a flow rate of 1.0 mL min-1. The instrument 
was fitted with a Polymer Labs aquagel-OH guard column (50 x 7.5 mm, 8 µm) followed by 
three PL aquagel-OH columns (30, 40 and 50; 300 x 7.5 mm, 8 µm). Narrow PEO standards 
(0.2 – 130 kDa) were used to calibrate the SEC. Molecular weights and dispersity values were 
calculated using Shimadzu LabSolutions software with SEC analysis add-on. 
The absence of unreacted DBCO-B12 in B12-PEG3k-lin-(GA24) and miktoarm azide-PEG3k-mik-
(GA17)3 targeted copolymers was evaluated with a Wyatt down 8+ 1200 infinity series in a 
system equipped with an Agilent PL aquagel-OH 8 µm SEC column. DPBS was used as the 
mobile phase, with a flow rate of 1 mL min-1 and UV detection at λ = 360 nm. The resulting 
chromatograms were analyzed using ASTRA® software V.6.1.2.84 (Wyatt Tech Corp).  
Size Exclusion – High Performance Liquid Chromatography (SE-HPLC). Analyses were carried 
out on a Shimadzu HPLC system (LC-20 AP pump). A Wyatt SEC 40 XL (300 x 7.8 mm) column 
(Bio Rad, Hercules, CA) was used, with 50 L samples being injected each time, with standard 
Dulbecco’s Phosphate Buffered Saline as the mobile phase, with UV detection at λ=280 nm, 
and fluorescence detection at λex,=  647 nm and λem,= 665 nm. 
Reversed-phase High Performance Liquid Chromatography (RP-HPLC). Analyses were 
carried out using a Shimadzu HPLC system (LC-20 AP pump) equipped with a Jupiter C18 300 
Å (250 x 4.6 mm) column (Phenomenex, Macclesfield, UK) with 50 L injection volume, with 
water/acetonitrile as the mobile phase in gradient from 5% to 90% v/v of acetonitrile and 
with UV detection at λ = 360 nm. 
α-dibenzocyclooctyne-vitamin B12 (DBCO-B12). DBCO-B12 was synthesized and characterized 
as described in the Materials and Methods section of the manuscript. RP-HPLC analysis of 
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cyanocobalamin (B12) starting material and final purified DBCO-B12 are shown in Figure S3 
below. 
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Figure S1. C18 RP HPLC chromatograms of α-dibenzocyclooctyne-vitamin B12, DBCO-B12, (top) and 
cyanocobalamin, vitamin B12, starting material (bottom). Water/acetonitrile was used as the mobile phase in 
gradient from 5% to 90% (v/v) of acetonitrile and UV detection at λ = 360 nm.  
3. Synthesis of polymers and intermediates. 
 
Figure S2. Synthesis of B12PEG3k-lin-GA24. Reactions and conditions: a. γ-benzyl-L-glutamate NCA, CH2Cl2, 5 days; 
b. p-toluene sulfonyl chloride, triethylamine, CH2Cl2, 12 h; c. NaN3, DMSO, 24 h; d. NaOH, H2O/THF, 2 days; e. α-













Figure S3. Synthesis of B12-PEG3k-mik-(GA17)3. Reactions and conditions: a. 3,4,5-tris(allyloxy)benzoic acid, DMTMM, 
methanol, 2 days; b. cysteamine hydrochloride, DPAP, MeOH, UV, 3 h; c. γ-benzyl-L-glutamate NCA, CH2Cl2, 5 days; d. p-
toluene sulfonyl chloride, triethylamine, CH2Cl2, 12 h; e. sodium azide, DMSO, 24 h; f. NaOH, H2O/THF, 2 days; g. α-





Hydroxy-PEG3k triallyl ether (D). O-(2-aminoethyl)polyethylene glycol 3.0 kDa (500 mg, 0.170 
mmol) was dissolved in toluene (50 mL) and solvent was then removed under reduced 
pressure. This process was repeated five times in order to remove traces of water from the 
PEG starting material before starting the reaction. 3,4,5-tris(allyloxy)benzoic acid (prepared 
as described previously[23], (73 mg, 0.25 mmol, 1.5 eq.), O-(2-aminoethyl)polyethylene glycol 
3.0 kDa (500 mg, 0.170 mmol, 1 eq.) and 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) (70 mg, 0.25 mmol, 1.5 eq.) were dissolved in 
anhydrous methanol (50 mL) under inert atmosphere. The mixture was stirred during two 
days at room temperature, after which time 1H NMR analysis showed that the reaction was 
completed (aromatics signals shifted from 7.35 to 7.20 ppm). The solvent was then removed 
under reduced pressure and the resulting residue suspended in 60 mL of water. Insoluble 
materials were removed by filtration, and the aqueous solution was dialyzed against water 
(MWCO 1 kDa) then freeze-dried.  Hydroxy-PEG3k triallyl ether (D) was isolated as a white 
solid (425 mg, 78 %). 1H NMR (400 MHz, MeOD, δ, ppm): 7.20 (s, CHaromatic), 6.19-6.04 (m, 
Hallyl), 5.55-5.15 (m, Hallyl), 4.68-4.56 (m, OCH2), 3.70-3.55 (s, OCH2 of PEG).  
Triamino-hydroxy-PEG3k (E). Hydroxy-PEG3k triallyl ether (D) (425 mg, 0.130 mmol, 1 eq.), 
cysteamine hydrochloride (160 mg, 2.07 mmol, 16 eq.) and 2,2-dimethoxy-2-
phenylacetophenone (DPAP) (10 mg, 0.039 mmol, 0.3 eq.) were dissolved in methanol (5 mL). 
The mixture was then irradiated using a 36 Watt UV Lamp equipped with 4 X 9 W Light bulbs 
at λ = 365 nm for 3 hours, when allyl signals could no longer be detected by 1H NMR. Methanol 
was then evaporated under reduced pressure and the resulting residue was suspended in 
water. The mixture was extracted with ethyl acetate to remove traces of DPAP and 
corresponding decomposition products. The aqueous phase was then dialyzed (MWCO 1 
kDa), and then freeze-dried. Triamino-hydroxy-PEG3k (E) was isolated as a white solid (352 
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mg, 77 %). 1H NMR (400 MHz, MeOD, δ, ppm): 7.20 (s, CHaromatic), 4.21-4.05 (m, OCH2), 3.70-
3.43 (s, OCH2 of PEG), 3.11 (m, CH2N), 2.80 (m, CH2S), 2.15-1.90 (m, OCH2CH2CH2S). 
 
Hydroxy-PEG3k-poly(benzyl-glutamic acid) copolymers (linear: (A), miktoarm: (F)): Triamino-
hydroxy-PEG3k (E) (91 mg, 0.026 mmol, 1 eq.) or commercially available O-(2-
aminoethyl)polyethylene glycol 3.0 kDa (200 mg, 0.0670 mmol, 1 eq.) were dissolved in dry 
dichloromethane (10 mL) in a round bottom flask. γ-Benzyl-L-glutamate NCA (821 mg, 3.12 
mmol, 120 eq.) or (2.11 g, 8.04 mmol, 120 eq.) to form hydroxy-PEG3k-mik-poly(OBn-GA17)3 
and hydroxy-PEG3k-lin-poly(OBn-GA24) copolymers, respectively, was dissolved in anhydrous 
dichloromethane (30 mL) and added to the solution containing the amino-PEG initiator. The 
mixture was stirred at room temperature under inert atmosphere. After 5 days the solutions 
were concentrated under vacuum (5 mL) and precipitated with diethyl ether to give the 
desired copolymers as white solids. The number of glutamic acid repeating units per polymer 
chain was estimated by 1H NMR, by comparing the integrals of the OCH2CH2 of the PEG block, 
with those of the OCH2 and phenyl groups of the OBn-GA repeating units. 
Hydroxy-PEG3k-lin-(OBn-GA24) (A) 493 mg. 1H NMR (400 MHz, CDCl3, δ, ppm): 7.40-7.15 (bs, 
CHaromatic), 5.13-4.93 (bs, C(O)OCH2), 4.00-3.80 (bs, HNCHCO), 3.72-3.56 (s, OCH2 of PEG), 2.70-
1.95 (m, CH2CH2C(O)O). 
Hydroxy-PEG3k-mik-(OBn-GA17)3 (F): 403 mg. 1H NMR (400 MHz, CDCl3, δ, ppm): 7.35-7.15 
(bs, CHaromatic), 5.16-4.92 (bs, C(O)OCH2), 4.05-3.80 (bs, HNCHCO), 3.69-3.57 (s, OCH2 of PEG), 
2.75-1.97 (m, CH2CH2C(O)O).  
p-toluene-sulfonyl-PEG3k-lin-(OBn-GA24) (B), and p-toluene-sulfonyl-PEG3k-mik-(OBn-GA17)3 
(G). Hydroxy-PEG3k-mik-(OBn-GA17)3 (G) (300 mg, 0.0120 mmol, 1 eq.) or hydroxy-PEG3k-lin-
poly(OBn-GA24) (B) (300 mg, 0.0300 mmol, 1 eq.) were dissolved in dry dichloromethane (50 
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mL) in a round bottom flask. While stirring, p-toluene sulfonyl chloride (23 mg, 0.12 mmol, 10 
eq. or 57.0 mg, 0.300 mmol, 10 eq.) and triethylamine (1.82 g, 18 mmol, 150 eq. or 1.52 mg, 
15 mmol, 50 eq.) were added to the solution containing the hydroxy-PEG3k-poly(benzyl-GA) 
copolymers. The reaction solutions were stirred at room temperature under inert 
atmosphere for 12 h. The mixtures were then neutralized with 1 M HCl, filtered and an excess 
of sodium bicarbonate was slowly added. The suspension was stirred, filtered again and the 
solutions concentrated to a volume of ca. 2 mL. Copolymers (B) and (G) were recovered by 
precipitation in diethyl ether, followed by filtration and removal of traces of solvent under 
reduced pressure.  
p-toluene-sulfonyl-PEG3k-lin-(OBn-GA24) (B) 213 mg, 67 %. 1H NMR (400 MHz, D2O, δ, ppm): 
7.79-7.74 (s, CHaromatic), 7.38-7.16 (s, CHaromatic), 7.14-7.10 (s, CHaromatic), 5.16-4.91 (bs, 
C(O)OCH2), 3.97-3.83 (bs, HNCHCO), 3.69-3.59 (bs, OCH2 of PEG), 2.65-2.0 (m, CH2CH2C(O)O).  
p-toluene-sulfonyl-PEG3k-mik-(OBn-GA17)3 (G) 153 mg, 50 %. 1H NMR (400 MHz, CDCl3, δ, 
ppm): 7.78-7.72 (s, CHaromatic), 7.39-7.15 (bs, CHaromatic), 7.11-7.06 (s, CHaromatic), 5.16-4.92 (bs, 
C(O)OCH2), 4.02-3.84 (bs, HNCHCO), 3.67-3.60 (s, OCH2 of PEG), 2.75-1.95 (m, CH2CH2C(O)O).  
 
Azide-PEG3k-lin-(OBn-GA24) (C) and azide-PEG3k-mik-(OBn-GA17)3 (H). p-toluene-sulfonyl-
PEG3k-lin-(OBn-GA24) (C) (200 mg, 0.0190 mmol, 1 eq.) or p-toluene-sulfonyl-PEG3k-mik-(OBn-
GA17)3 (H) (150 mg, 0.006 mmol, 1 eq.) were dissolved in anhydrous DMSO (5 mL) in a round 
bottom flask. Sodium azide (12 mg, 0.19 mmol, 10 eq.; or 4 mg, 0.06 mmol, 10 eq.) to form 
azide-PEG3k-lin-(OBn-GA24) and azide-PEG3k-mik-(OBn-GA17)3 copolymers, respectively was 
added to the round bottom flask. The solutions were stirred at room temperature under inert 
atmosphere for 24 h. The reaction solution was then added to an excess of diethyl ether, and 
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the residue dissolved in THF and filtered again. The solvent was then removed under reduced 
pressure to give the desired azide-functionalized copolymers.  
Azide-PEG3k-lin-(OBn-GA24) (C). 113 mg. FT-IR: 2089 cm-1 (ῡN3). 
Azide-PEG3k-mik-(OBn-GA17)3 (H). 98 mg. FT-IR: 2042 cm-1 (ῡN3).  
 
Azide-PEG3k-lin-(GA24) (1) and azide-PEG3k-mik-(GA17)3 (2). Azide-PEG3k-lin-(OBn-GA24) (C) 
(113 mg, 0.0110 mmol), or azide-PEG3k-mik-(OBn-GA17)3 (H) (98 mg, 0.0040 mmol) were 
dissolved in THF in a round bottom flask. 10 or 28 µL of a 1.0 M NaOH aqueous solution (2.5 
equiv. of NaOH per benzyl group) were then slowly added under vigorous stirring to hydrolyze 
benzyl ester repeating units. The reaction was left to stir for 2 days at room temperature, 
then the solvents were removed under reduce pressure. The residue was dissolved in 
deionized water (50 mL) and the resulting solution was dialyzed (MWCO 3.5 kDa). The solution 
was then freeze-dried to give the desired copolymers as off-white solids.  
Azide-PEG3k-lin-(GA24) (1) 76 mg. 1H NMR (400 MHz, D2O, δ, ppm): 7.76-7.66 (s, CHaromatic), 
7.48-7.32 (s, CHaromatic), 4.44-4.02 (bs, HNCHCO), 3.77-3.59 (s, OCH2 of PEG), 2.48-1.83 (m, 
CH2CH2COOH). 
Azide-PEG3k-mik-(GA17)3 (2). 60 mg. 1H NMR (400 MHz, D2O, δ, ppm): 4.44-4.26 (bs, HNCHCO), 
3.77-3.63 (s, OCH2 of PEG), 2.38-1.85 (m, CH2CH2COOH).  
 
B12-PEG3k-lin-(GA24) and B12-PEG3k-mik-(GA17)3 were synthesized by Cu-free alkyne-azide 
cycloaddition of α-dibenzocyclooctyne-vitamin B12 (DBCO-B12), and azide-PEG3k-lin-(GA24) (1) 
and azide-PEG3k-mik-(GA17)3 (2), respectively, and characterized as described in the Materials 
and Methods section of the manuscript. Reversed-phase HPLC (RP-HPLC) analysis of B12 
(DBCO-B12), and B12-PEG3k-lin-(GA24) and B12-PEG3k-mik-(GA17)3, (Figure S4), and the 
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calibration curve used to quantify the efficiency of the cycloaddition reaction (Figure S5), are 
shown below. 
 
Figure S4. C18 RP-HPLC chromatograms of B12-PEG3k-lin-(GA24) and B12-PEG3k-mik-(GA17)3 copolymers, and free α-
dibenzocyclooctyne-vitamin B12 (DBCO-B12). Water/acetonitrile was used as the mobile phase in gradient from 
5% to 90% (v/v) of acetonitrile and UV detection at λ = 360 nm. 
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Figure S5. Efficiency (%) of attachment of DBCO-B12 to azide-functional linear mPEG3k-poly(GA) copolymers, was 
calculated by UV-vis analysis (λ = 540 nm), using deionized water as the solvent.  The figures shows the 
calibration curve utilized for this calculation, which was built using cyanocobalamin (B12) solutions of known 
concentration.  
 
Cu-free alkyne-azide cycloaddition using DBCO-B12: NMR investigation. HSQC NMR 
(together with UV-vis spectrometry) was used to monitor the copper-free click cycloaddition 
of DBCO-B12 and azide-PEG3k-lin-(GA24) (1), and azide-PEG3k-mik-(GA17)3 (2). Given the 
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complexity of the NMR spectra of these polymers, a small-scale synthesis of simpler 
cyclooctyne and azide compounds was carried out (Figure S6), and the corresponding 
cycloadducts characterized by HSQC NMR. Accordingly, 1,2,3-triazoles (4) were synthesized 
in two steps from dibenzocyclooctyne-amine, and HSQC NMR confirmed the success of the 
click reaction with 2-(2-(2-azidoethoxy)ethoxy)ethanol, with low field shift of the α-CH2 
signals of the dibenzocyclooctyne-carbamate (3) at 5.2/56 ppm to 6.1/52 ppm (1H/13C 
signals).  Signals for both regioisomeric cycloadducts were clearly visible in the spectrum of 
the purified products (4) and (4)’ (Figure S7). An analogous shift was observed when 
dibenzocyclooctyne-carbamate (3) was replaced by DBCO-B12 (Figure S7). 
 
 






Figure S7.  2D HSQC NMR spectra showing the shift of the α-CH2 proton signals of the α-dibenzocyclooctyne ring 




dibenzo[b,g][1,2,3]triazolo[4,5-d]azocin-8-yl)-3-oxopropyl)carbamate (4) and (4)’. 
Dibenzocyclooctyne-amine (20 mg, 0.072 mmol, 1.0 eq.) was dissolved in DCM (2 mL) and 
reacted with an excess of ethyl chloroformate (16 mg, 0.14 mmol, 2.0 eq.) and triethylamine 
(15 mg, 0.14 mmol, 2.0 eq.) under stirring for 24 h, to give the intermediate (3). Methanol (2 
mL) was then added to quench the excess of ethyl chloroformate and 2-(2-(2-
azidoethoxy)ethoxy)ethanol (25 mg, 0.145 mmol, 2.0 eq.) was added. After 12 h, and after 12 
a1 a2







hours (4) and (4)’ were purified by preparative TLC, and isolated as a mixture of the two 
regioadducts 2D HSQC NMR is shown in Figure S7. 
Cyanocobalamin (3-(1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1,13-dihydro-8H-
dibenzo[b,g][1,2,3]triazolo[4,5-d]azocin-8-yl)-3-oxopropyl)carbamate (5) and (5)’. DBCO-B12 
(10 mg, 0.0060 mmol, 1.0 eq.) was added to a solution of 2-(2-(2-azidoethoxy)ethoxy)ethanol 
(3.1 mg, 0.018 mmol, 3.0 eq.) in DMSO (1 mL). Purification by preparative TLC (iPrOH/n-
BuOH/H2O/NH4OH 30/45/21/4) gave the desired clicked cycloadducts (5) and (5)’. 2D HSQC 
NMR (Figure S7) showed patterns for the methylene signals of the cyclooctyne (a, a’), and its 
correspondent cycloadduct (b, and b’) analogous to those observed for the B12-PEG3k-lin-
(GA24) and B12-PEG3k-mik-(GA17)3 targeted copolymers (Figure 1 of the manuscript), thus 
further confirming the successful grafting of cyanocobalamin (B12) to the corresponding azide-
functional polymer precursors  
56 
 
4. Synthesis of cyanocobalamin fluorescent probe pyr-B12. 
 
Figure S8. Synthesis of pyranine-tagged vitamin cyanocobalamin (pyr-B12). Reactions and conditions: a. i. 1,1′-
carbonyldiimidazole, DMSO ii. 2,2′-(ethylenedioxy)bis(ethylamine); b. methyl bromoacetate, DIPEA, methanol 




Pyranine methyl ester (6). 8-Hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine, 
1.00 g, 1.91 mmol, 1 eq.) was added to methanol (60 mL) and heated to reflux under stirring 
to ensure full dissolution, protected from light. Methyl bromoacetate (1.11 g, 7.24 mmol, 3.8 
eq.) and DIPEA (N,N-diisopropylethylamine, 0.690 g, 5.32 mmol, 2.8 eq.) were dissolved in 
methanol (6 mL) in a separate flask, and the resulting solution added portion wise - a third of 
the total volume every 1.5 hours, to the refluxing solution of pyranine. The resulting yellow 
mixture was further refluxed for 3 hours, still protected from light, and then left stirring at 
room temperature overnight before precipitation in isopropanol. The solid was then collected 
by centrifugation, residual traces of solvent were removed under reduced pressure, and the 
resulting crude product (6) used for the next step without further purification. Yield: 938 mg, 
82 %. 1H NMR (400 MHz, methanol-d4) δ 9.44 (s, 1H, CHaromatic), 9.28 (d, J = 9.7 Hz, 1H, 
CHaromatic), 9.26 (d, J = 9.7 Hz, 1H, CHaromatic), 9.18 (d, J = 9.8 Hz, 1H, CHaromatic), 8.75 (d, J = 9.6 
Hz, 1H, CHaromatic), 8.32 (s, 1H, CHaromatic), 5.21 (s, 2H, OCH2), 3.87 (s, 3H, OCH3). ESI-TOF mass 
spectrometry: expected m/z [M – Na+] 618.89, found 618.90. 
Carboxyl pyranine (7). Pyranine methyl ester (6) (200 mg, 0.336 mmol, 1 eq.) was dissolved 
in deionised water (5 ml) containing sodium hydroxide (16 mg, 0.40 mmol, 1.2 eq.), and the 
resulting solution stirred at 60°C for 30 min. After cooling to room temperature, the solution 
was neutralised with aqueous hydrochloric acid, and the desired product was precipitated in 
isopropanol. The orange precipitate was collected by vacuum filtration, and residual traces of 
solvent were removed under reduced pressure, to give the intermediate (7) as an orange 
solid. Yield: 104 mg, 53%. 1H NMR (400 MHz, methanol-d4) δ 9.44 (s, 1H, CHaromatic), 9.28 (d, J 
= 9.7 Hz, 1H, CHaromatic), 9.26 (d, J = 9.7 Hz, 1H, CHaromatic), 9.18 (d, J = 9.8 Hz, 1H, CHaromatic), 
8.79 (d, J = 9.6 Hz, 1H, CHaromatic), 5.16 (s, 2H, OCH2. ESI-TOF mass spectrometry: expected m/z 
[M – Na+] 604.88, found 604.88. 
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Amino cyanocobalamin (B12-NH2). Carbonyldiimidazole (CDI) (144 mg, 0.890 mmol, 4 eq.) 
was added to cyanocobalamin (0.300 g, 0.221 mmol, 1 eq.) previously dissolved in anhydrous 
dimethyl sulfoxide (DMSO) (10 mL). The mixture was stirred for 2 h at 30°C.  2,2′-
(Ethylenedioxy)bis(ethylamine) (132 mg, 0.89 mmol, 4 eq.) was then added, and the mixture 
stirred at room temperature for further 24 h. The mixture was poured into ethyl acetate, and 
the resulting precipitate was isolated by centrifugation and purified by silica column 
chromatography (mobile phase: 30:45:4:21 2-propanol: n-butanol: ammonia (1M) : water 
vol:vol:vol:vol) and then lyophilized. Yield: 68 mg, 21%. ESI-TOF mass spectrometry: expected 
m/z [M+] 1529.68, found 1529.67. 
Pyranine B12 fluorescent probe (pyr-B12). Carboxypyranine (7) (16 mg, 0.028 mmol, 2eq.) and 
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (8 mg, 0.06 
mmol, 4 eq.) were dissolved in methanol, in separate flasks (2 ml of methanol per flask). The 
DMTMM solution was added to the carboxypyranine solution dropwise, and the resulting 
solution left to stir for 1 h at room temperature, followed by addition of a solution of B12-NH2 
(20 mg, 0.014 mmol, 1 eq.) in methanol (5 mL). The resulting mixture was left to stir overnight 
at room temperature, concentrated under reduced pressure, and the product purified by 
preparative thin layer chromatography (TLC) (30:40:4:26 2-propanol: n-butanol: ammonia 
(1M) : water vol:vol:vol:vol), extracting the desired fluorescent pyr-B12 probe from the 
relevant TLC band with methanol (yield: 7.7 mg, 54%). . 1H NMR (400 MHz, MeOD, δ, ppm): 
the appearance of the peaks between 9.5-8.5 which corresponded to the aromatic groups 
within the pyranine structure confirmed the success of conjugation. ESI-TOF mass 





































































* * * * * * * *
 
Figure S9.  Cellular internalization of pyr-B12 fluorescent probe by Caco-2 the presence or absence of free B12 
competitive ligand, as assessed by flow cytometry. Control: untreated cells. One-way ANOVA was used for 
statistical analysis. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001.  λex : 401 nm and λem : 421 nm. Caco-2 
cells are known to express both cubilin [72]and TCN2 B12 [42] receptors, and ‘free’ B12 is a competitor to both 
transport mechanism.  
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Figure S10. Particle size distribution of lysozyme complexes assembled from non-targeted mPEG2k-lin-GA30 and mPEG2k-mik-
(GA10)3; and targeted B12-PEG3k-lin-GA24 and B12-PEG3k-mik-(GA17)3, as assessed by nanoparticle tracking analysis (NTA). B12-
PEG3k-lin-(GA24) and B12-PEG3k-mik-(GA17)3 (bottom panels) refer to complexes assembled with 85:15 mol:mol B12-









Figure S11. TEM images of lysozyme-mPEG2k-lin-GA30 complexes prepared at r: 2.5 as detailed in method section. Image 
scale bar: (Left) 200 nm and (right) 500 nm. TEM analysis was performed using a Tecnai G2 (FEI, Oregon, USA). Images were 
captured using Megaview III.  Lysozyme-mPEG2k-lin-GA30 nanocomplexes prepared at r 2.5 were loaded at a protein 
concentration of 70 μg mL-1. Samples were prepared by placing complexes suspension onto 3.05 mm Nickel grid, 




Figure S12. Electrophoretic mobility of protein (lysozyme), polymer (mPEG-lin-GA30), and lysozyme-mPEG2k-lin-GA30 
complexes prepared at r: 2.5 following incubation in a) cell culture medium (DMEM, pH 7.4 without phenol red), and b) in 
simulated lysosomal environment at pH 4.5 (a 50 : 50 mixture of 1 M sodium acetate and 1 M hydrochloric acid). Incubated 
samples were withdrawn and 50 µl loaded in each well on a 1% agarose gel, run 2 h at 100 mA in trisacetate-EDTA buffer. 






5. Synthesis of Lysozyme-Cyanine 5 (Lysozyme-Cy5) 
Lysozyme (40 mg, 2.8 µmol, 1 equiv) was dissolved in 4.5 mL of a 100 mM sodium bicarbonate 
solution, pH 8.4. Cyanine 5 NHS ester (4.9 mg, 6.4 µmol, 3 equiv) was then dissolved in 10 mM 
phosphate buffer before being added slowly to the lysozyme solution, and the resulting 
reaction mixture was very gently stirred overnight, protected from light. The mixture was then 
dialyzed against deionized water using 10 kDa MWCO dialysis membrane. The absence of free 
unreacted Cyanine 5 dye was confirmed by size exclusion - high performance liquid 
chromatography (SE-HPLC). The degree of labelling– defined as the average number of dye 
molecules per protein - of lysozyme after dialysis was determined to be   ̴0.7 by using Tech 
Tip #31 Calculate dye:protein (F/P) molar ratios equations [73]. 
 
6. Dry powders: Particle size distribution on Transwell® inserts 
Preparation of polymer-lysozyme complexes and corresponding dry powder formulations is 
described in the Materials and Methods section of the manuscript. 
Calu-3 cells were cultured on Transwell® inserts over 21 days as described in main paper [74]. 
Culture medium was then removed and dry powders were sprayed twice (2 mg per dose) 
using a Dry Powder InsufflatorTM model DP4-M® (Penn-Century®) into the Transwell® inserts 
as follows [25]:  
Four Transwell® inserts were placed into a desiccator at equal distance from the center (Figure 
S11) as previously shown within our group. 2 mg of dry powder formulations were then 
sprayed twice from a Penn-Century® device. Next, 0.5 mL of Hank’s Balanced Salts Solution 
(HBSS) were added to the basolateral chamber of the Transwell® inserts and cells were 
incubated at 37°C and 5% CO2 for 3 h. Cells were then detached with trypsin/EDTA, washed 
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twice with DPBS and lysozyme-Cy5 uptake was analyzed by flow cytometry in quadruplicate 
experiments, with more than 10,000 cells measured in each sample.  
 
 
Figure S13. Spraying of dry powder formulations on top of Calu-3 cell monolayers using a Penn-Century® 
device.  
 
Table S1. Emitted mass, particle size (D50) and uniformity of mass delivery of dry powder formulations tested in study. 
All formulations contain 10% (w/w) leucine, 6.6% (w/w) buffer salts and up to 100% (w/w) trehalose. a See UDP, UDP-P and 
UDP-TC composition in Table 1 (main paper). b D50 represents the diameter below which 50% of the particle population lie. c 
Emitted mass was determined by accurately weighing the blister before and after aerosolisation of powders using a fast 
screening impactor (FSI, Copley Scientific) –uniformity of mass delivered expressed as RSD (Relative Standard Deviation). d 
corresponding to ~ 5 % w/w of lysozyme. 
 
To ensure that all Transwell® inserts placed into the desiccator receive similar dose, particle 
size (D90) and particle distribution were investigated. 2 mg of dry powder formulations were 
sprayed twice from a Penn-Century® device as shown in Figure S7, and each Transwell® insert 

















UDP 0% Complexes 83 ± 10 4.1 ± 0.2 11% 
UDP-P 5% Lysozyme 93 ± 4 4.3 ± 0.6 5% 
UDP-TC 10% Complexesd 93 ± 7 4.4 ± 0.6 10% 
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Software to give D90 – diameter below which 90% of the particle population lie – and dry 
powder distribution. 
 
Figure S14. Dry powder distribution after spraying them twice (2 mg per dose) using a Penn-Century device. 
Four Transwell® inserts were used for each formulation. Each big square contains up to 900 small colored 
squares that correspond to each image taken from each Transwell® insert by an optical microscope. The 
different colors depends on the particle concentration on each image.  Light green: 0% of particles, green: 5% 
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0.03 0.00 0.05 0.04 0.07 0.05 0.11 0.12 0.05 0.28 0.13 0.33 0.24 0.13 0.22 0.14 0.13 0.11 0.10 0.05 0.13 0.01
0.14 0.22 0.04 0.23 0.07 0.68 0.27 0.45 0.21 0.21 0.18 1.23 1.68 0.25 0.22 0.29 0.20 0.26 0.43 0.12 0.04 0.29 0.15
0.99 0.03 0.15 0.10 0.33 0.57 0.28 0.46 1.27 0.29 0.32 0.26 0.25 0.24 0.35 0.27 0.90 0.21 0.18 0.53 0.46 0.06 0.58 0.89 0.17 0.03
0.03 0.18 0.83 0.53 0.85 0.53 0.39 0.14 0.35 0.98 2.10 0.60 0.49 0.80 0.49 0.42 0.57 0.68 0.31 0.21 0.12 0.13 0.10 0.03 0.06 0.04 0.05
0.25 0.09 0.11 0.26 0.56 0.48 1.69 0.44 0.60 1.23 0.69 0.88 0.86 0.50 0.52 0.65 0.23 1.51 0.38 0.35 0.17 0.08 0.10 0.07
0.68 0.08 0.50 0.33 0.63 0.69 0.52 1.51 2.25 1.57 0.61 1.59 0.75 0.78 1.22 0.57 0.40 0.41 0.49 0.39 0.19 0.15 0.02
0.40 0.37 0.29 1.23 0.81 0.73 0.54 0.75 1.28 0.78 0.44 1.23 1.60 1.67 2.46 0.73 0.72 0.98 0.88 0.43 0.14 0.22 0.10 0.12 0.09 0.07 0.03
0.22 0.28 0.45 0.30 0.63 0.75 1.06 1.48 1.02 0.71 0.83 1.08 1.09 1.54 1.34 0.88 0.70 0.68 0.88 0.72 0.26 1.07 0.39 0.12 0.08 0.04 0.10 0.16
0.17 0.28 0.34 0.35 0.79 1.05 0.49 1.18 1.39 1.13 1.27 0.90 1.94 0.96 1.86 1.25 1.56 0.82 1.45 0.71 0.77 0.38 0.39 0.27 0.24 0.17 0.06 0.08
0.45 0.28 0.23 0.74 1.22 1.27 0.96 1.13 1.29 1.12 1.71 1.03 1.54 0.81 0.95 3.10 1.70 0.64 2.23 1.72 0.72 0.59 0.22 0.47 0.25 0.28 0.20
0.11 0.27 0.69 1.47 1.70 1.61 1.11 0.98 1.19 1.18 0.65 2.29 0.82 1.42 1.62 1.62 1.89 0.96 0.30 0.63 0.62 0.13 0.22 0.12 0.02 0.04
0.25 0.32 0.37 0.55 0.48 2.07 1.22 1.42 1.11 1.09 1.60 1.46 1.56 1.61 1.29 1.12 1.06 1.04 0.86 1.40 1.16 1.33 1.00 0.59 0.49 0.43 0.09 0.13 0.52
0.08 0.15 0.26 0.56 0.59 0.71 1.01 1.21 2.10 1.00 1.27 1.87 1.36 1.50 1.12 1.38 1.13 1.08 1.27 0.98 1.99 1.17 0.48 0.37 0.43 0.07 0.15 0.09
0.14 0.51 0.33 0.45 0.67 0.62 1.36 0.99 1.22 1.28 1.29 1.30 1.41 1.22 1.36 1.05 0.78 0.76 1.42 1.04 1.19 1.50 0.83 0.82 0.54 0.33 0.19 0.26 0.35
0.10 0.04 1.74 0.25 0.25 0.52 0.81 1.34 1.11 0.82 1.16 1.02 1.19 1.59 1.39 1.61 1.42 1.01 1.74 1.36 1.02 0.88 0.80 0.41 0.39 0.34 0.06 0.09
0.07 0.34 0.38 0.18 0.50 0.31 0.37 0.52 1.10 0.91 1.10 1.46 1.62 1.63 1.27 2.13 1.45 1.28 0.81 1.48 0.52 0.86 0.41 0.43 0.37
0.03 0.08 0.15 0.14 0.25 0.30 0.42 0.33 0.55 0.28 1.18 0.88 1.16 1.44 1.05 1.31 0.75 0.77 1.23 0.94 0.64 0.43 0.27
0.09 0.09 0.10 0.07 0.75 0.41 0.31 0.30 0.38 0.98 0.48 1.03 0.80 1.07 1.01 1.33 1.07 0.89 1.01 0.82 0.56
0.01 0.05 0.19 0.10 0.18 0.14 0.30 0.25 0.23 0.41 0.19 0.34 0.59 0.53 0.75 0.76 0.59 0.68 0.89
0.35 0.02 0.19 0.10 0.12 0.12 0.20 0.18 0.21 0.67 0.40 0.46 0.31
0.06 0.09 0.09 0.02 0.30 0.57 0.33 0.55 0.31



















Table S2. Particle size distribution (d90) of dry powders after spraying twice (2 mg per dose) using a Penn Century device. 
Four Transwell® inserts were used for each formulation. All dry powder contains phosphate buffer salts (6.6% w/w), leucine 





Figure S15. Distribution in lung tissue samples of red labelled Cy5-lysozyme, the blue fluorescent nuclear stain  
DAPI and merged images at different time points following  administration of 2 mg of dry powder formulation 
to healthy mice using the pulmonary delivery device Penn-Century;  LDP-P (free protein dry powder 
formulation),  LDP-NT (non-targeted complexes dry powder formulation, and LDP-TC (targeted complexes dry 
powder formulation). Untreated mice were used as a negative control. The representative examples shown in 
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 Particle size distribution d90 (μm) 









Free lysozyme 3.9 6.6 6.5 5.6 
mPEG2k-lin-GA30 6.0  5.1  5.7 5.6 
mPEG2k-mik-(GA10)3 6.2 6.7 7.1 6.1 
B12-PEG3k-lin-(GA24) 4.9 3.8 7.3 6.4 





α-dibenzocyclooctyne-vitamin B12 (DBCO-B12) 
Cyanocobalamin (vitamin B12, 135 mg, 0.0995 mmol, 1 eq.) was dissolved in anhydrous DMSO 
(10 mL) under inert atmosphere. CDI (32.2 mg, 0.199 mmol, 2 eq.) was then added to the 
round bottom flask and the reaction was stirred at 30°C for 1.5 h prior to addition of 
dibenzocyclooctyne-amine (100 mg, 0.362 mmol, 3.65 eq.) in DMSO (5 mL). The resulting pink 
solution was then stirred at room temperature protected from light for a further 24 h, 
precipitated in diethyl ether, and the pink solid was collected by filtration, following re-
solubilisation in methanol. The product was then purified by preparative-TLC (30:45:4:21 2-
propanol: n-butanol: ammonia: water vol:vol:vol:vol) and extracted using methanol.  
Chemical identity of DBCO-B12 was confirmed by MS - expected m/z [M-Na++] theor. 851.85, 




7. NMR spectra 
 




Figure S17. 1H NMR spectrum of carboxypyranine (7) in CH3OD. 
 
 





Figure S19. 1H NMR spectrum of triamino-hydroxy-PEG3k (E) in CH3OD. 
 





Figure S21. 1H NMR spectrum of p-toluene-sulfonyl-PEG3k-mik-(OBn-GA17)3 (G) in CDCl3. 
 
 




Figure S23.  1H NMR spectrum of B12-PEG3k-mik-p(GA17)3 in D2O. 
 
 




Figure S25. 1H NMR spectrum of p-toluene-sulfonyl-PEG3k-lin-(GA24) (B) in CDCl3. 
 
 





Figure S27. 1H NMR spectrum of B12-PEG3k-lin-GA24 in D2O. 
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